{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T04:49:57Z","timestamp":1777438197509,"version":"3.51.4"},"reference-count":377,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,31]],"date-time":"2022-12-31T00:00:00Z","timestamp":1672444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,31]],"date-time":"2022-12-31T00:00:00Z","timestamp":1672444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["SFRH\/BD\/112526\/2015"],"award-info":[{"award-number":["SFRH\/BD\/112526\/2015"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDB\/00709\/2020"],"award-info":[{"award-number":["UIDB\/00709\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDP\/04378\/2020"],"award-info":[{"award-number":["UIDP\/04378\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDP\/00709\/2020"],"award-info":[{"award-number":["UIDP\/00709\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDB\/04378\/2020"],"award-info":[{"award-number":["UIDB\/04378\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"crossref","award":["Centro-01-0145-FEDER-000019-C4"],"award-info":[{"award-number":["Centro-01-0145-FEDER-000019-C4"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100008530","name":"Fondo Europeo de Desarrollo Regional","doi-asserted-by":"crossref","award":["PT17\/0019\/0001"],"award-info":[{"award-number":["PT17\/0019\/0001"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Spanish Government","award":["SEV2017-0712"],"award-info":[{"award-number":["SEV2017-0712"]}]},{"name":"Portuguese Pharmacists Order","award":["BInov 2021"],"award-info":[{"award-number":["BInov 2021"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s00018-022-04670-y","type":"journal-article","created":{"date-parts":[[2022,12,31]],"date-time":"2022-12-31T08:02:40Z","timestamp":1672473760000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Vitreous humor proteome: unraveling the molecular mechanisms underlying proliferative and neovascular vitreoretinal diseases"],"prefix":"10.1007","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4041-1504","authenticated-orcid":false,"given":"F\u00e1tima Milhano","family":"dos Santos","sequence":"first","affiliation":[]},{"given":"Sergio","family":"Ciordia","sequence":"additional","affiliation":[]},{"given":"Joana","family":"Mesquita","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o Paulo Castro","family":"de Sousa","sequence":"additional","affiliation":[]},{"given":"Alberto","family":"Paradela","sequence":"additional","affiliation":[]},{"given":"C\u00e2ndida Teixeira","family":"Tomaz","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6910-7576","authenticated-orcid":false,"given":"Lu\u00eds Ant\u00f3nio Paulino","family":"Passarinha","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2022,12,31]]},"reference":[{"key":"4670_CR1","doi-asserted-by":"publisher","first-page":"e1164","DOI":"10.1016\/S2214-109X(17)30412-6","volume":"5","author":"C Sabanayagam","year":"2017","unstructured":"Sabanayagam C, Cheng C-Y (2017) Global causes of vision loss in 2015: are we on track to achieve the Vision 2020 target? Lancet Glob Heal 5:e1164\u2013e1165. https:\/\/doi.org\/10.1016\/S2214-109X(17)30412-6","journal-title":"Lancet Glob Heal"},{"key":"4670_CR2","doi-asserted-by":"publisher","first-page":"e888","DOI":"10.1016\/S2214-109X(17)30293-0","volume":"5","author":"RRA Bourne","year":"2017","unstructured":"Bourne RRA, Flaxman SR, Braithwaite T et al (2017) Magnitude, temporal trends, and projections of the global prevalence of blindness and distance and near vision impairment: a systematic review and meta-analysis. Lancet Glob Heal 5:e888\u2013e897. https:\/\/doi.org\/10.1016\/S2214-109X(17)30293-0","journal-title":"Lancet Glob Heal"},{"key":"4670_CR3","first-page":"71","volume":"30","author":"P Ackland","year":"2018","unstructured":"Ackland P, Resnikoff S, Bourne R (2018) World blindness and visual impairment: despite many successes, the problem is growing. Community Eye Heal 30:71\u201373","journal-title":"Community Eye Heal"},{"key":"4670_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(21)00031-0","author":"BK Swenor","year":"2021","unstructured":"Swenor BK, Ehrlich JR (2021) Comment Ageing and vision loss: looking to the future. Lancet. https:\/\/doi.org\/10.1016\/S2214-109X(21)00031-0","journal-title":"Lancet"},{"key":"4670_CR5","doi-asserted-by":"publisher","first-page":"4329","DOI":"10.1007\/s00018-017-2651-5","volume":"74","author":"S Yoshida","year":"2017","unstructured":"Yoshida S, Nakama T, Ishikawa K et al (2017) Periostin in vitreoretinal diseases. Cell Mol Life Sci 74:4329\u20134337. https:\/\/doi.org\/10.1007\/s00018-017-2651-5","journal-title":"Cell Mol Life Sci"},{"key":"4670_CR6","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1001\/archopht.124.10.1457","volume":"124","author":"EJ Kuiper","year":"2006","unstructured":"Kuiper EJ, De Smet MD, Van Meurs JC et al (2006) Association of connective tissue growth factor with fibrosis in vitreoretinal disorders in the human eye. Arch Ophthalmol 124:1457\u20131462. https:\/\/doi.org\/10.1001\/archopht.124.10.1457","journal-title":"Arch Ophthalmol"},{"key":"4670_CR7","doi-asserted-by":"crossref","unstructured":"Constable IJ, Nagpal M (2013) Proliferative vitreoretinopathy. In: Retina, 5th edn. Elsevier, pp 1806\u20131825","DOI":"10.1016\/B978-1-4557-0737-9.00107-7"},{"key":"4670_CR8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.preteyeres.2015.07.005","volume":"51","author":"JC Pastor","year":"2016","unstructured":"Pastor JC, Rojas J, Pastor-Idoate S et al (2016) Proliferative vitreoretinopathy: a new concept of disease pathogenesis and practical consequences. Prog Retin Eye Res 51:125\u2013155. https:\/\/doi.org\/10.1016\/j.preteyeres.2015.07.005","journal-title":"Prog Retin Eye Res"},{"key":"4670_CR9","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1002\/pmic.201300075","volume":"13","author":"RD Semba","year":"2013","unstructured":"Semba RD, Enghild JJ, Venkatraman V et al (2013) The Human Eye Proteome Project: perspectives on an emerging proteome. Proteomics 13:2500\u20132511. https:\/\/doi.org\/10.1002\/pmic.201300075","journal-title":"Proteomics"},{"key":"4670_CR10","doi-asserted-by":"publisher","first-page":"e843","DOI":"10.1016\/S2214-109X(17)30302-9","volume":"5","author":"J Ramke","year":"2017","unstructured":"Ramke J, Gilbert CE (2017) Universal eye health: are we getting closer? Lancet Glob Heal 5:e843\u2013e844. https:\/\/doi.org\/10.1016\/S2214-109X(17)30302-9","journal-title":"Lancet Glob Heal"},{"key":"4670_CR11","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/prca.201400133","volume":"9","author":"JP Monteiro","year":"2015","unstructured":"Monteiro JP, Santos FM, Rocha AS et al (2015) Vitreous humor in the pathologic scope: Insights from proteomic approaches. PROTEOMICS Clin Appl 9:187\u2013202. https:\/\/doi.org\/10.1002\/prca.201400133","journal-title":"PROTEOMICS Clin Appl"},{"key":"4670_CR12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1167\/tvst.7.5.12","volume":"7","author":"G Velez","year":"2018","unstructured":"Velez G, Tang PH, Cabral T et al (2018) Personalized proteomics for precision health: identifying biomarkers of vitreoretinal disease. Transl Vis Sci Technol 7:12. https:\/\/doi.org\/10.1167\/tvst.7.5.12","journal-title":"Transl Vis Sci Technol"},{"key":"4670_CR13","doi-asserted-by":"publisher","first-page":"739","DOI":"10.4236\/jbise.2013.67091","volume":"06","author":"M Kodama","year":"2013","unstructured":"Kodama M, Matsuura T, Hara Y (2013) Structure of vitreous body and its relationship with liquefaction. J Biomed Sci Eng 06:739\u2013745. https:\/\/doi.org\/10.4236\/jbise.2013.67091","journal-title":"J Biomed Sci Eng"},{"key":"4670_CR14","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/978-1-4939-3305-1_12","volume-title":"Handbook of biomaterial properties","author":"TV Chirila","year":"2016","unstructured":"Chirila TV, Hong Y (2016) Chapter C2 the vitreous humor. Handbook of biomaterial properties. Springer New York, New York, pp 125\u2013134"},{"key":"4670_CR15","doi-asserted-by":"crossref","unstructured":"Sebag J (2010) Vitreous Anatomy, Aging, and Anomalous Posterior Vitreous Detachment. In: Encyclopedia of the Eye. Elsevier, pp 307\u2013315","DOI":"10.1016\/B978-0-12-374203-2.00256-6"},{"key":"4670_CR16","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1038\/eye.2008.21","volume":"22","author":"MM Le Goff","year":"2008","unstructured":"Le Goff MM, Bishop PN (2008) Adult vitreous structure and postnatal changes. Eye 22:1214\u20131222. https:\/\/doi.org\/10.1038\/eye.2008.21","journal-title":"Eye"},{"key":"4670_CR17","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1159\/000353447","volume":"230","author":"MD De Smet","year":"2013","unstructured":"De Smet MD, Gad Elkareem AM, Zwinderman AH (2013) The vitreous, the retinal interface in ocular health and disease. Ophthalmologica 230:165\u2013178. https:\/\/doi.org\/10.1159\/000353447","journal-title":"Ophthalmologica"},{"key":"4670_CR18","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/3172138","author":"C Alovisi","year":"2017","unstructured":"Alovisi C, Panico C, De Sanctis U, Eandi CM (2017) Vitreous substitutes: old and new materials in vitreoretinal surgery. Journal of ophthalmology. https:\/\/doi.org\/10.1155\/2017\/3172138","journal-title":"Journal of ophthalmology"},{"key":"4670_CR19","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ajo.2009.07.036","volume":"149","author":"NM Holekamp","year":"2010","unstructured":"Holekamp NM (2010) The vitreous gel: more than meets the eye. Am J Ophthalmol 149:32-36.e1. https:\/\/doi.org\/10.1016\/j.ajo.2009.07.036","journal-title":"Am J Ophthalmol"},{"key":"4670_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/pmic.201700394","volume":"18","author":"MT Ahmad","year":"2018","unstructured":"Ahmad MT, Zhang P, Dufresne C et al (2018) The human eye proteome project: updates on an emerging proteome. Proteomics 18:1\u201331. https:\/\/doi.org\/10.1002\/pmic.201700394","journal-title":"Proteomics"},{"key":"4670_CR21","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/prca.201300062","volume":"8","author":"VB Mahajan","year":"2014","unstructured":"Mahajan VB, Skeie JM (2014) Translational vitreous proteomics. Proteomics Clin Appl 8:204\u2013208. https:\/\/doi.org\/10.1002\/prca.201300062","journal-title":"Proteomics Clin Appl"},{"key":"4670_CR22","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.preteyeres.2010.07.001","volume":"29","author":"TL Ponsioen","year":"2010","unstructured":"Ponsioen TL, Hooymans JMMM, Los LI (2010) Remodelling of the human vitreous and vitreoretinal interface\u2014a dynamic process. Prog Retin Eye Res 29:580\u2013595. https:\/\/doi.org\/10.1016\/j.preteyeres.2010.07.001","journal-title":"Prog Retin Eye Res"},{"key":"4670_CR23","unstructured":"World Health Organization (2019) World report on vision"},{"key":"4670_CR24","doi-asserted-by":"publisher","first-page":"e1221","DOI":"10.1016\/S2214-109X(17)30393-5","volume":"5","author":"SR Flaxman","year":"2017","unstructured":"Flaxman SR, Bourne RRA, Resnikoff S et al (2017) Global causes of blindness and distance vision impairment 1990\u20132020: a systematic review and meta-analysis. Lancet Glob Heal 5:e1221\u2013e1234. https:\/\/doi.org\/10.1016\/S2214-109X(17)30393-5","journal-title":"Lancet Glob Heal"},{"key":"4670_CR25","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.2337\/db16-1453","volume":"66","author":"AR Santos","year":"2017","unstructured":"Santos AR, Ribeiro L, Bandello F et al (2017) Functional and structural findings of neurodegeneration in early stages of diabetic retinopathy: cross-sectional analyses of baseline data of the EUROCONDOR project. Diabetes 66:2503\u20132510. https:\/\/doi.org\/10.2337\/db16-1453","journal-title":"Diabetes"},{"key":"4670_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/jci.insight.93751","volume":"2","author":"EJ Duh","year":"2017","unstructured":"Duh EJ, Sun JK, Stitt AW (2017) Diabetic retinopathy: current understanding, mechanisms, and treatment strategies. JCI Insight 2:1\u201313. https:\/\/doi.org\/10.1172\/jci.insight.93751","journal-title":"JCI Insight"},{"key":"4670_CR27","doi-asserted-by":"publisher","first-page":"556","DOI":"10.2337\/dc11-1909","volume":"35","author":"JWY Yau","year":"2012","unstructured":"Yau JWY, Rogers SL, Kawasaki R et al (2012) Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 35:556\u2013564. https:\/\/doi.org\/10.2337\/dc11-1909","journal-title":"Diabetes Care"},{"key":"4670_CR28","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/ceo.12696","volume":"44","author":"DSW Ting","year":"2016","unstructured":"Ting DSW, Cheung GCM, Wong TY (2016) Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review. Clin Exp Ophthalmol 44:260\u2013277. https:\/\/doi.org\/10.1111\/ceo.12696","journal-title":"Clin Exp Ophthalmol"},{"key":"4670_CR29","doi-asserted-by":"publisher","first-page":"364","DOI":"10.4093\/dmj.2018.0182","volume":"42","author":"S Kusuhara","year":"2018","unstructured":"Kusuhara S, Fukushima Y, Ogura S et al (2018) Pathophysiology of diabetic retinopathy: the old and the new. Diabetes Metab J 42:364\u2013376. https:\/\/doi.org\/10.4093\/dmj.2018.0182","journal-title":"Diabetes Metab J"},{"key":"4670_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms19061816","volume":"19","author":"W Wang","year":"2018","unstructured":"Wang W, Lo ACY (2018) Diabetic retinopathy: pathophysiology and treatments. Int J Mol Sci 19:1\u201314. https:\/\/doi.org\/10.3390\/ijms19061816","journal-title":"Int J Mol Sci"},{"key":"4670_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnins.2019.01172","volume":"13","author":"MG Rossino","year":"2019","unstructured":"Rossino MG, Dal Monte M, Casini G (2019) Relationships between neurodegeneration and vascular damage in diabetic retinopathy. Front Neurosci 13:1\u201320. https:\/\/doi.org\/10.3389\/fnins.2019.01172","journal-title":"Front Neurosci"},{"key":"4670_CR32","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/ceo.13894","volume":"49","author":"MJ Gale","year":"2021","unstructured":"Gale MJ, Scruggs BA, Flaxel CJ (2021) Diabetic eye disease: a review of screening and management recommendations. Clin Experiment Ophthalmol 49:128\u2013145. https:\/\/doi.org\/10.1111\/ceo.13894","journal-title":"Clin Experiment Ophthalmol"},{"key":"4670_CR33","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.visres.2017.04.003","volume":"139","author":"J Lechner","year":"2017","unstructured":"Lechner J, O\u2019Leary OE, Stitt AW (2017) The pathology associated with diabetic retinopathy. Vision Res 139:7\u201314. https:\/\/doi.org\/10.1016\/j.visres.2017.04.003","journal-title":"Vision Res"},{"key":"4670_CR34","doi-asserted-by":"publisher","first-page":"E2655","DOI":"10.1073\/pnas.1522014113","volume":"113","author":"EH Sohn","year":"2016","unstructured":"Sohn EH, van Dijk HW, Jiao C et al (2016) Retinal neurodegeneration may precede microvascular changes characteristic of diabetic retinopathy in diabetes mellitus. Proc Natl Acad Sci 113:E2655\u2013E2664. https:\/\/doi.org\/10.1073\/pnas.1522014113","journal-title":"Proc Natl Acad Sci"},{"key":"4670_CR35","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1172\/JCI31030","volume":"117","author":"M Friedlander","year":"2007","unstructured":"Friedlander M (2007) Fibrosis and diseases of the eye. J Clin Invest 117:576\u2013586. https:\/\/doi.org\/10.1172\/JCI31030","journal-title":"J Clin Invest"},{"key":"4670_CR36","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.preteyeres.2014.05.002","volume":"42","author":"SA Kandarakis","year":"2014","unstructured":"Kandarakis SA, Piperi C, Topouzis F, Papavassiliou AG (2014) Emerging role of advanced glycation-end products (AGEs) in the pathobiology of eye diseases. Prog Retin Eye Res 42:85\u2013102. https:\/\/doi.org\/10.1016\/j.preteyeres.2014.05.002","journal-title":"Prog Retin Eye Res"},{"key":"4670_CR37","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.preteyeres.2019.03.002","volume":"109","author":"IM Nawaz","year":"2019","unstructured":"Nawaz IM, Rezzola S, Cancarini A et al (2019) Human vitreous in proliferative diabetic retinopathy: characterization and translational implications. Prog Retin Eye Res 109:110\u2013119. https:\/\/doi.org\/10.1016\/j.preteyeres.2019.03.002","journal-title":"Prog Retin Eye Res"},{"key":"4670_CR38","doi-asserted-by":"crossref","unstructured":"Kroll P, Rodrigues EB, Meyer CH (2014) III.L. Proliferative diabetic vitreoretinopathy. In: Vitreous. Springer New York, New York, pp 421\u2013434","DOI":"10.1007\/978-1-4939-1086-1_24"},{"key":"4670_CR39","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jprot.2016.06.034","volume":"150","author":"\u00c9 Cs\u0151sz","year":"2017","unstructured":"Cs\u0151sz \u00c9, De\u00e1k E, Kall\u00f3 G et al (2017) Diabetic retinopathy: proteomic approaches to help the differential diagnosis and to understand the underlying molecular mechanisms. J Proteomics 150:351\u2013358. https:\/\/doi.org\/10.1016\/j.jprot.2016.06.034","journal-title":"J Proteomics"},{"key":"4670_CR40","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.3390\/jcm10112309","volume":"10","author":"SR Weber","year":"2021","unstructured":"Weber SR, Zhao Y, Gates C et al (2021) Proteomic analyses of vitreous in proliferative diabetic retinopathy: prior studies and future outlook. J Clin Med 10:2309. https:\/\/doi.org\/10.3390\/jcm10112309","journal-title":"J Clin Med"},{"key":"4670_CR41","doi-asserted-by":"publisher","first-page":"4755","DOI":"10.3390\/ijms20194755","volume":"20","author":"H Youngblood","year":"2019","unstructured":"Youngblood H, Robinson R, Sharma A, Sharma S (2019) Proteomic biomarkers of retinal inflammation in diabetic retinopathy. Int J Mol Sci 20:4755. https:\/\/doi.org\/10.3390\/ijms20194755","journal-title":"Int J Mol Sci"},{"key":"4670_CR42","doi-asserted-by":"publisher","DOI":"10.1111\/aos.15168","author":"MS Hansen","year":"2022","unstructured":"Hansen MS, Rasmussen M, Grauslund J et al (2022) Proteomic analysis of vitreous humour of eyes with diabetic macular oedema: a systematic review. Acta Ophthalmol. https:\/\/doi.org\/10.1111\/aos.15168","journal-title":"Acta Ophthalmol"},{"key":"4670_CR43","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S1570-0232(02)00078-8","volume":"776","author":"T Nakanishi","year":"2002","unstructured":"Nakanishi T, Koyama R, Ikeda T, Shimizu A (2002) Catalogue of soluble proteins in the human vitreous humor: comparison between diabetic retinopathy and macular hole. J Chromatogr B Anal Technol Biomed Life Sci 776:89\u2013100. https:\/\/doi.org\/10.1016\/S1570-0232(02)00078-8","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci"},{"key":"4670_CR44","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1074\/mcp.M300038-MCP200","volume":"2","author":"K Yamane","year":"2003","unstructured":"Yamane K, Minamoto A, Yamashita H et al (2003) Proteome analysis of human vitreous proteins. Mol Cell Proteomics 2:1177\u20131187. https:\/\/doi.org\/10.1074\/mcp.M300038-MCP200","journal-title":"Mol Cell Proteomics"},{"key":"4670_CR45","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/978-1-59745-432-2_23","volume-title":"Proteomics of human body fluids","author":"A Minamoto","year":"2007","unstructured":"Minamoto A, Yamane K, Yokoyama T (2007) Proteomics of vitreous fluid. In: Thongboonkerd V (ed) Proteomics of human body fluids, 1st edn. Humana Press, Totowa, pp 495\u2013507","edition":"1"},{"key":"4670_CR46","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1002\/prca.200800017","volume":"2","author":"T Shitama","year":"2008","unstructured":"Shitama T, Hayashi H, Noge S et al (2008) Proteome profiling of vitreoretinal diseases by cluster analysis. Proteomics Clin Appl 2:1265\u20131280. https:\/\/doi.org\/10.1002\/prca.200800017","journal-title":"Proteomics Clin Appl"},{"key":"4670_CR47","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1080\/02713680600557030","volume":"31","author":"SJ Kim","year":"2006","unstructured":"Kim SJ, Kim SJ, Park J et al (2006) Differential expression of vitreous proteins in proliferative diabetic retinopathy. Curr Eye Res 31:231\u2013240. https:\/\/doi.org\/10.1080\/02713680600557030","journal-title":"Curr Eye Res"},{"key":"4670_CR48","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1007\/s00125-007-0627-y","volume":"50","author":"M Garc\u00eda-Ram\u00edrez","year":"2007","unstructured":"Garc\u00eda-Ram\u00edrez M, Canals F, Hern\u00e1ndez C et al (2007) Proteomic analysis of human vitreous fluid by fluorescence-based difference gel electrophoresis (DIGE): a new strategy for identifying potential candidates in the pathogenesis of proliferative diabetic retinopathy. Diabetologia 50:1294\u20131303. https:\/\/doi.org\/10.1007\/s00125-007-0627-y","journal-title":"Diabetologia"},{"key":"4670_CR49","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1001\/archopht.126.8.1076","volume":"126","author":"R Sim\u00f3","year":"2008","unstructured":"Sim\u00f3 R, Higuera M, Garc\u00eda-Ram\u00edrez M et al (2008) Elevation of apolipoprotein A-I and apolipoprotein H levels in the vitreous fluid and overexpression in the retina of diabetic patients. Arch Ophthalmol 126:1076\u20131081. https:\/\/doi.org\/10.1001\/archopht.126.8.1076","journal-title":"Arch Ophthalmol"},{"key":"4670_CR50","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.exer.2005.01.020","volume":"81","author":"M Ouchi","year":"2005","unstructured":"Ouchi M, West K, Crabb JW et al (2005) Proteomic analysis of vitreous from diabetic macular edema. Exp Eye Res 81:176\u2013182. https:\/\/doi.org\/10.1016\/j.exer.2005.01.020","journal-title":"Exp Eye Res"},{"key":"4670_CR51","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/dmrr.2419","volume":"29","author":"C Hern\u00e1ndez","year":"2013","unstructured":"Hern\u00e1ndez C, Garc\u00eda-Ram\u00edrez M, Colom\u00e9 N et al (2013) Identification of new pathogenic candidates for diabetic macular edema using fluorescence-based difference gel electrophoresis analysis. Diabetes Metab Res Rev 29:499\u2013506. https:\/\/doi.org\/10.1002\/dmrr.2419","journal-title":"Diabetes Metab Res Rev"},{"key":"4670_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1477-5956-10-15","volume":"10","author":"H Wang","year":"2012","unstructured":"Wang H, Feng L, Hu J et al (2012) Characterisation of the vitreous proteome in proliferative diabetic retinopathy. Proteome Sci 10:1\u201311. https:\/\/doi.org\/10.1186\/1477-5956-10-15","journal-title":"Proteome Sci"},{"key":"4670_CR53","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nm1534","volume":"13","author":"BB Gao","year":"2007","unstructured":"Gao BB, Clermont A, Rook S et al (2007) Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nat Med 13:181\u2013188. https:\/\/doi.org\/10.1038\/nm1534","journal-title":"Nat Med"},{"key":"4670_CR54","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1021\/pr800112g","volume":"7","author":"B-B Gao","year":"2008","unstructured":"Gao B-B, Chen X, Timothy N et al (2008) Characterization of the vitreous proteome in diabetes without diabetic retinopathy and diabetes with proliferative diabetic retinopathy. J Proteome Res 7:2516\u20132525. https:\/\/doi.org\/10.1021\/pr800112g","journal-title":"J Proteome Res"},{"key":"4670_CR55","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.ophtha.2005.10.030","volume":"113","author":"H Funatsu","year":"2006","unstructured":"Funatsu H, Yamashita H, Nakamura S et al (2006) Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 113:294\u2013301. https:\/\/doi.org\/10.1016\/j.ophtha.2005.10.030","journal-title":"Ophthalmology"},{"key":"4670_CR56","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ophtha.2008.09.037","volume":"116","author":"H Funatsu","year":"2009","unstructured":"Funatsu H, Noma H, Mimura T et al (2009) Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology 116:73\u201379. https:\/\/doi.org\/10.1016\/j.ophtha.2008.09.037","journal-title":"Ophthalmology"},{"key":"4670_CR57","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1002\/elps.201400049","volume":"35","author":"AS Rocha","year":"2014","unstructured":"Rocha AS, Santos FM, Monteiro JP et al (2014) Trends in proteomic analysis of human vitreous humor samples. Electrophoresis 35:2495\u20132508. https:\/\/doi.org\/10.1002\/elps.201400049","journal-title":"Electrophoresis"},{"key":"4670_CR58","doi-asserted-by":"publisher","first-page":"5115","DOI":"10.1007\/s00216-019-01887-y","volume":"411","author":"FM Santos","year":"2019","unstructured":"Santos FM, Albuquerque T, Gaspar LM et al (2019) Refinement of two-dimensional electrophoresis for vitreous proteome profiling using an artificial neural network. Anal Bioanal Chem 411:5115\u20135126. https:\/\/doi.org\/10.1007\/s00216-019-01887-y","journal-title":"Anal Bioanal Chem"},{"key":"4670_CR59","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1021\/pr901013d","volume":"9","author":"K Kim","year":"2010","unstructured":"Kim K, Kim SJ, Yu HG et al (2010) Verification of biomarkers for diabetic retinopathy by multiple reaction monitoring. J Proteome Res 9:689\u2013699. https:\/\/doi.org\/10.1021\/pr901013d","journal-title":"J Proteome Res"},{"key":"4670_CR60","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.exer.2012.11.023","volume":"108","author":"H Wang","year":"2013","unstructured":"Wang H, Feng L, Hu J et al (2013) Differentiating vitreous proteomes in proliferative diabetic retinopathy using high-performance liquid chromatography coupled to tandem mass spectrometry. Exp Eye Res 108:110\u2013119. https:\/\/doi.org\/10.1016\/j.exer.2012.11.023","journal-title":"Exp Eye Res"},{"key":"4670_CR61","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s12886-018-0821-3","volume":"18","author":"J Li","year":"2018","unstructured":"Li J, Lu Q, Lu P (2018) Quantitative proteomics analysis of vitreous body from type 2 diabetic patients with proliferative diabetic retinopathy. BMC Ophthalmol 18:151. https:\/\/doi.org\/10.1186\/s12886-018-0821-3","journal-title":"BMC Ophthalmol"},{"key":"4670_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1178641816686078","volume":"8","author":"S Balaiya","year":"2017","unstructured":"Balaiya S, Zhou Z, Chalam KV (2017) Characterization of vitreous and aqueous proteome in humans with proliferative diabetic retinopathy and its clinical correlation. Proteomics Insights 8:1\u201310. https:\/\/doi.org\/10.1177\/1178641816686078","journal-title":"Proteomics Insights"},{"key":"4670_CR63","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1167\/iovs.18-24122","volume":"59","author":"C Schori","year":"2018","unstructured":"Schori C, Trachsel C, Grossmann J et al (2018) The proteomic landscape in the vitreous of patients with age-related and diabetic retinal disease. Invest Ophthalmol Vis Sci 59:31\u201340. https:\/\/doi.org\/10.1167\/iovs.18-24122","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4670_CR64","doi-asserted-by":"publisher","first-page":"5131","DOI":"10.1021\/acs.jproteome.5b00900","volume":"14","author":"S Loukovaara","year":"2015","unstructured":"Loukovaara S, Nurkkala H, Tamene F et al (2015) Quantitative proteomics analysis of vitreous humor from diabetic retinopathy patients. J Proteome Res 14:5131\u20135143. https:\/\/doi.org\/10.1021\/acs.jproteome.5b00900","journal-title":"J Proteome Res"},{"key":"4670_CR65","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.visres.2017.03.006","volume":"139","author":"TW Gardner","year":"2017","unstructured":"Gardner TW, Sundstrom JM (2017) A proposal for early and personalized treatment of diabetic retinopathy based on clinical pathophysiology and molecular phenotyping. Vision Res 139:153\u2013160. https:\/\/doi.org\/10.1016\/j.visres.2017.03.006","journal-title":"Vision Res"},{"key":"4670_CR66","doi-asserted-by":"publisher","first-page":"4203","DOI":"10.1002\/pmic.200700745","volume":"7","author":"T Kim","year":"2007","unstructured":"Kim T, Sang JK, Kim K et al (2007) Profiling of vitreous proteomes from proliferative diabetic retinopathy and nondiabetic patients. Proteomics 7:4203\u20134215. https:\/\/doi.org\/10.1002\/pmic.200700745","journal-title":"Proteomics"},{"key":"4670_CR67","doi-asserted-by":"publisher","first-page":"3588","DOI":"10.2337\/db15-0317","volume":"64","author":"T Kita","year":"2015","unstructured":"Kita T, Clermont AC, Murugesan N et al (2015) Plasma kallikrein-kinin system as a VEGF-independent mediator of diabetic macular edema. Diabetes 64:3588\u20133599. https:\/\/doi.org\/10.2337\/db15-0317","journal-title":"Diabetes"},{"key":"4670_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12014-018-9187-z","volume":"15","author":"C Zou","year":"2018","unstructured":"Zou C, Han C, Zhao M et al (2018) Change of ranibizumab-induced human vitreous protein profile in patients with proliferative diabetic retinopathy based on proteomics analysis. Clin Proteomics 15:1\u201310. https:\/\/doi.org\/10.1186\/s12014-018-9187-z","journal-title":"Clin Proteomics"},{"key":"4670_CR69","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1159\/000342977","volume":"49","author":"UE Koskela","year":"2013","unstructured":"Koskela UE, Kuusisto SM, Nissinen AE et al (2013) High vitreous concentration of IL-6 and IL-8, but not of adhesion molecules in relation to plasma concentrations in proliferative diabetic retinopathy. Ophthalmic Res 49:108\u2013114. https:\/\/doi.org\/10.1159\/000342977","journal-title":"Ophthalmic Res"},{"key":"4670_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0187304","volume":"12","author":"I Klaassen","year":"2017","unstructured":"Klaassen I, de Vries EW, Vogels IMC et al (2017) Identification of proteins associated with clinical and pathological features of proliferative diabetic retinopathy in vitreous and fibrovascular membranes. PLoS ONE 12:1\u201321. https:\/\/doi.org\/10.1371\/journal.pone.0187304","journal-title":"PLoS ONE"},{"key":"4670_CR71","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/eye.2017.285","volume":"32","author":"G Srividya","year":"2018","unstructured":"Srividya G, Jain M, Mahalakshmi K et al (2018) A novel and less invasive technique to assess cytokine profile of vitreous in patients of diabetic macular oedema. Eye 32:820\u2013829. https:\/\/doi.org\/10.1038\/eye.2017.285","journal-title":"Eye"},{"key":"4670_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0110531","volume":"9","author":"J Wang","year":"2014","unstructured":"Wang J, Chen S, Jiang F et al (2014) Vitreous and plasma VEGF levels as predictive factors in the progression of proliferative diabetic retinopathy after vitrectomy. PLoS ONE 9:1\u20138. https:\/\/doi.org\/10.1371\/journal.pone.0110531","journal-title":"PLoS ONE"},{"key":"4670_CR73","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1080\/08977194.2018.1477140","volume":"36","author":"J Mesquita","year":"2018","unstructured":"Mesquita J, Castro-de-Sousa JP, Vaz-Pereira S et al (2018) Evaluation of the growth factors VEGF-a and VEGF-B in the vitreous and serum of patients with macular and retinal vascular diseases. Growth Factors 36:48\u201357. https:\/\/doi.org\/10.1080\/08977194.2018.1477140","journal-title":"Growth Factors"},{"key":"4670_CR74","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3390\/medsci5030017","volume":"5","author":"J Mesquita","year":"2017","unstructured":"Mesquita J, Castro de Sousa J, Vaz-Pereira S et al (2017) VEGF-B levels in the vitreous of diabetic and non-diabetic patients with ocular diseases and its correlation with structural parameters. Med Sci 5:17. https:\/\/doi.org\/10.3390\/medsci5030017","journal-title":"Med Sci"},{"key":"4670_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7573\/dic.212532","volume":"7","author":"Y Zhao","year":"2018","unstructured":"Zhao Y, Singh RP (2018) The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy. Drugs Context 7:1\u201310. https:\/\/doi.org\/10.7573\/dic.212532","journal-title":"Drugs Context"},{"key":"4670_CR76","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1080\/07853890.2022.2064541","volume":"54","author":"A Arrigo","year":"2022","unstructured":"Arrigo A, Aragona E, Bandello F (2022) VEGF-targeting drugs for the treatment of retinal neovascularization in diabetic retinopathy. Ann Med 54:1089\u20131111. https:\/\/doi.org\/10.1080\/07853890.2022.2064541","journal-title":"Ann Med"},{"key":"4670_CR77","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1001\/jamaophthalmol.2017.0821","volume":"135","author":"SB Bressler","year":"2017","unstructured":"Bressler SB, Liu D, Glassman AR et al (2017) Change in diabetic retinopathy through 2 years secondary analysis of a randomized clinical trial comparing aflibercept, bevacizumab, and ranibizumab. JAMA Ophthalmol 135:558\u2013568. https:\/\/doi.org\/10.1001\/jamaophthalmol.2017.0821","journal-title":"JAMA Ophthalmol"},{"key":"4670_CR78","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","volume":"372","author":"S Cai","year":"2015","unstructured":"Cai S, Bressler NM (2015) Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 372:1193\u20131203. https:\/\/doi.org\/10.1056\/NEJMoa1414264","journal-title":"N Engl J Med"},{"key":"4670_CR79","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.115.017472.Critical","volume":"133","author":"W Zhang","year":"2016","unstructured":"Zhang W, Qu X, Chen B et al (2016) Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology 133:48\u201361. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.017472.Critical","journal-title":"Ophthalmology"},{"key":"4670_CR80","doi-asserted-by":"publisher","first-page":"516","DOI":"10.2337\/diacare.24.3.516","volume":"24","author":"C Hern\u00e1ndez","year":"2001","unstructured":"Hern\u00e1ndez C, Burgos R, Cant\u00f3n A et al (2001) Vitreous levels of vascular cell adhesion molecule and vascular endothelial growth factor in patients with proliferative diabetic retinopathy: a case-control study. Diabetes Care 24:516\u2013521. https:\/\/doi.org\/10.2337\/diacare.24.3.516","journal-title":"Diabetes Care"},{"key":"4670_CR81","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/ceo.12891","volume":"45","author":"W Chen","year":"2017","unstructured":"Chen W, Lu Q, Lu L, Guan H (2017) Increased levels of alphaB-crystallin in vitreous fluid of patients with proliferative diabetic retinopathy and correlation with vascular endothelial growth factor. Clin Exp Ophthalmol 45:379\u2013384. https:\/\/doi.org\/10.1111\/ceo.12891","journal-title":"Clin Exp Ophthalmol"},{"key":"4670_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2005.08.066","author":"E Ishizaki","year":"2006","unstructured":"Ishizaki E, Takai S, Ueki M et al (2006) Correlation between angiotensin-converting enzyme, vascular endothelial growth factor, and matrix metalloproteinase-9 in the vitreous of eyes with diabetic retinopathy. Am J Ophthalmol. https:\/\/doi.org\/10.1016\/j.ajo.2005.08.066","journal-title":"Am J Ophthalmol"},{"key":"4670_CR83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0085857","volume":"8","author":"AM Abu El-Asrar","year":"2013","unstructured":"Abu El-Asrar AM, Mohammad G, Nawaz MI et al (2013) Relationship between vitreous levels of matrix metalloproteinases and vascular endothelial growth factor in proliferative diabetic retinopathy. PLoS ONE 8:1\u201311. https:\/\/doi.org\/10.1371\/journal.pone.0085857","journal-title":"PLoS ONE"},{"key":"4670_CR84","first-page":"2663","volume":"15","author":"H Izuta","year":"2009","unstructured":"Izuta H, Chikaraishi Y, Adachi T et al (2009) Extracellular SOD and VEGF are increased in vitreous bodies from proliferative diabetic retinopathy patients. Mol Vis 15:2663\u20132672","journal-title":"Mol Vis"},{"key":"4670_CR85","first-page":"130","volume":"16","author":"H Izuta","year":"2010","unstructured":"Izuta H, Matsunaga N, Shimazawa M et al (2010) Proliferative diabetic retinopathy and relations among antioxidant activity, oxidative stress, and VEGF in the vitreous body. Mol Vis 16:130\u2013136","journal-title":"Mol Vis"},{"key":"4670_CR86","first-page":"649","volume":"21","author":"V Brzovi\u0107-\u0160ari\u0107","year":"2015","unstructured":"Brzovi\u0107-\u0160ari\u0107 V, Landeka I, \u0160ari\u0107 B et al (2015) Levels of selected oxidative stress markers in the vitreous and serum of diabetic retinopathy patients. Mol Vis 21:649\u2013664","journal-title":"Mol Vis"},{"key":"4670_CR87","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1136\/bjo.86.3.311","volume":"86","author":"H Funatsu","year":"2002","unstructured":"Funatsu H, Yamashita H, Nakanishi Y, Hori S (2002) Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. Br J Ophthalmol 86:311\u2013315. https:\/\/doi.org\/10.1136\/bjo.86.3.311","journal-title":"Br J Ophthalmol"},{"key":"4670_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/5140521","volume":"2019","author":"M Whitehead","year":"2019","unstructured":"Whitehead M, Osborne A, Widdowson PS et al (2019) Angiopoietins in diabetic retinopathy: current understanding and therapeutic potential. J Diabetes Res 2019:1\u20139. https:\/\/doi.org\/10.1155\/2019\/5140521","journal-title":"J Diabetes Res"},{"key":"4670_CR89","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/s41433-020-01377-x","volume":"35","author":"AM Joussen","year":"2021","unstructured":"Joussen AM, Ricci F, Paris LP et al (2021) Angiopoietin\/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data. Eye 35:1305\u20131316. https:\/\/doi.org\/10.1038\/s41433-020-01377-x","journal-title":"Eye"},{"key":"4670_CR90","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.ophtha.2019.03.023","volume":"126","author":"J Sahni","year":"2019","unstructured":"Sahni J, Patel SS, Dugel PU et al (2019) Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-a with faricimab in diabetic macular edema. Ophthalmology 126:1155\u20131170. https:\/\/doi.org\/10.1016\/j.ophtha.2019.03.023","journal-title":"Ophthalmology"},{"key":"4670_CR91","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1080\/13543784.2021.1879791","volume":"30","author":"M Nicol\u00f2","year":"2021","unstructured":"Nicol\u00f2 M, Ferro Desideri L, Vagge A, Traverso CE (2021) Faricimab: an investigational agent targeting the Tie-2\/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert Opin Investig Drugs 30:193\u2013200. https:\/\/doi.org\/10.1080\/13543784.2021.1879791","journal-title":"Expert Opin Investig Drugs"},{"key":"4670_CR92","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.ajo.2004.10.004","volume":"139","author":"D Watanabe","year":"2005","unstructured":"Watanabe D, Suzuma K, Suzuma I et al (2005) Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Am J Ophthalmol 139:476\u2013481. https:\/\/doi.org\/10.1016\/j.ajo.2004.10.004","journal-title":"Am J Ophthalmol"},{"key":"4670_CR93","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1159\/000339952","volume":"228","author":"M Huber","year":"2012","unstructured":"Huber M, Wachtlin J (2012) Vitreous levels of proteins implicated in angiogenesis are modulated in patients with retinal or choroidal neovascularization. Ophthalmologica 228:188\u2013193. https:\/\/doi.org\/10.1159\/000339952","journal-title":"Ophthalmologica"},{"key":"4670_CR94","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1136\/bjo.2004.049940","volume":"89","author":"JI Patel","year":"2005","unstructured":"Patel JI, Hykin PG, Gregor ZJ et al (2005) Angiopoietin concentrations in diabetic retinopathy. Br J Ophthalmol 89:480\u2013483. https:\/\/doi.org\/10.1136\/bjo.2004.049940","journal-title":"Br J Ophthalmol"},{"key":"4670_CR95","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/j.1755-3768.2012.02473.x","volume":"91","author":"S Loukovaara","year":"2013","unstructured":"Loukovaara S, Robciuc A, Holopainen JM et al (2013) Ang-2 up-regulation correlates with increased levels of MMP-9, VEGF, EPO and TGF\u03b21 in diabetic eyes undergoing vitrectomy. Acta Ophthalmol 91:531\u2013539. https:\/\/doi.org\/10.1111\/j.1755-3768.2012.02473.x","journal-title":"Acta Ophthalmol"},{"key":"4670_CR96","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S0002-9394(02)01538-6","volume":"134","author":"R Sim\u00f3","year":"2002","unstructured":"Sim\u00f3 R, Lecube A, Segura RM et al (2002) Free insulin growth factor-I and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. Am J Ophthalmol 134:376\u2013382","journal-title":"Am J Ophthalmol"},{"key":"4670_CR97","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/eye.2016.246","volume":"31","author":"E Al Kahtani","year":"2017","unstructured":"Al Kahtani E, Xu Z, Al Rashaed S et al (2017) Vitreous levels of placental growth factor correlate with activity of proliferative diabetic retinopathy and are not influenced by bevacizumab treatment. Eye 31:529\u2013536. https:\/\/doi.org\/10.1038\/eye.2016.246","journal-title":"Eye"},{"key":"4670_CR98","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1007\/s10384-011-0004-8","volume":"55","author":"Y Suzuki","year":"2011","unstructured":"Suzuki Y, Nakazawa M, Suzuki K et al (2011) Expression profiles of cytokines and chemokines in vitreous fluid in diabetic retinopathy and central retinal vein occlusion. Jpn J Ophthalmol 55:256\u2013263. https:\/\/doi.org\/10.1007\/s10384-011-0004-8","journal-title":"Jpn J Ophthalmol"},{"key":"4670_CR99","doi-asserted-by":"publisher","first-page":"6523","DOI":"10.1167\/iovs.15-16793","volume":"56","author":"K Kovacs","year":"2015","unstructured":"Kovacs K, Marra KV, Yu G et al (2015) Angiogenic and inflammatory vitreous biomarkers associated with increasing levels of retinal ischemia. Investig Ophthalmol Vis Sci 56:6523\u20136530. https:\/\/doi.org\/10.1167\/iovs.15-16793","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"4670_CR100","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1080\/02713680802585920","volume":"34","author":"A Praidou","year":"2009","unstructured":"Praidou A, Klangas I, Papakonstantinou E et al (2009) Vitreous and serum levels of platelet-derived growth factor and their correlation in patients with proliferative diabetic retinopathy. Curr Eye Res 34:152\u2013161. https:\/\/doi.org\/10.1080\/02713680802585920","journal-title":"Curr Eye Res"},{"key":"4670_CR101","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.exer.2005.10.002","volume":"82","author":"JI Patel","year":"2006","unstructured":"Patel JI, Tombran-Tink J, Hykin PG et al (2006) Vitreous and aqueous concentrations of proangiogenic, antiangiogenic factors and other cytokines in diabetic retinopathy patients with macular edema: Implications for structural differences in macular profiles. Exp Eye Res 82:798\u2013806. https:\/\/doi.org\/10.1016\/j.exer.2005.10.002","journal-title":"Exp Eye Res"},{"key":"4670_CR102","doi-asserted-by":"crossref","first-page":"7585","DOI":"10.3390\/ijms23147585","volume":"23","author":"MR Munk","year":"2022","unstructured":"Munk MR, Somfai GM, De Smet MD et al (2022) The role of intravitreal corticosteroids in the treatment of DME: predictive OCT biomarkers. Int J Mol Sci 23:7585","journal-title":"Int J Mol Sci"},{"key":"4670_CR103","doi-asserted-by":"publisher","first-page":"233","DOI":"10.4103\/tjo.tjo_68_19","volume":"9","author":"J Chawan-Saad","year":"2019","unstructured":"Chawan-Saad J, Wu M, Wu A, Wu L (2019) Corticosteroids for diabetic macular edema. Taiwan J Ophthalmol 9:233. https:\/\/doi.org\/10.4103\/tjo.tjo_68_19","journal-title":"Taiwan J Ophthalmol"},{"key":"4670_CR104","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.3390\/cells10051049","volume":"10","author":"JO Wallsh","year":"2021","unstructured":"Wallsh JO, Gallemore RP (2021) Anti-VEGF-resistant retinal diseases: a review of the latest treatment options. Cells 10:1049. https:\/\/doi.org\/10.3390\/cells10051049","journal-title":"Cells"},{"key":"4670_CR105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/571456","volume":"2015","author":"BA Mysona","year":"2015","unstructured":"Mysona BA, Matragoon S, Stephens M et al (2015) Imbalance of the nerve growth factor and its precursor as a potential biomarker for diabetic retinopathy. Biomed Res Int 2015:1\u201312. https:\/\/doi.org\/10.1155\/2015\/571456","journal-title":"Biomed Res Int"},{"key":"4670_CR106","doi-asserted-by":"publisher","first-page":"5594","DOI":"10.1167\/iovs.17-21973","volume":"58","author":"JD Boss","year":"2017","unstructured":"Boss JD, Singh PK, Pandya HK et al (2017) Assessment of neurotrophins and inflammatory mediators in vitreous of patients with diabetic retinopathy. Investig Opthalmology Vis Sci 58:5594. https:\/\/doi.org\/10.1167\/iovs.17-21973","journal-title":"Investig Opthalmology Vis Sci"},{"key":"4670_CR107","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/bjophthalmol-2014-306366","volume":"99","author":"S Yoshida","year":"2015","unstructured":"Yoshida S, Kubo Y, Kobayashi Y et al (2015) Increased vitreous concentrations of MCP-1 and IL-6 after vitrectomy in patients with proliferative diabetic retinopathy: possible association with post-operative macular oedema. Br J Ophthalmol 99:960\u2013966. https:\/\/doi.org\/10.1136\/bjophthalmol-2014-306366","journal-title":"Br J Ophthalmol"},{"key":"4670_CR108","doi-asserted-by":"publisher","first-page":"e0248439","DOI":"10.1371\/journal.pone.0248439","volume":"16","author":"S Deuchler","year":"2021","unstructured":"Deuchler S, Schubert R, Singh P et al (2021) Vitreous expression of cytokines and growth factors in patients with diabetic retinopathy\u2014an investigation of their expression based on clinical diabetic retinopathy grade. PLoS ONE 16:e0248439. https:\/\/doi.org\/10.1371\/journal.pone.0248439","journal-title":"PLoS ONE"},{"key":"4670_CR109","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12886-022-02439-2","volume":"22","author":"CYJ Kuo","year":"2022","unstructured":"Kuo CYJ, Murphy R, Rupenthal ID, Mugisho OO (2022) Correlation between the progression of diabetic retinopathy and inflammasome biomarkers in vitreous and serum\u2014a systematic review. BMC Ophthalmol 22:1\u201313. https:\/\/doi.org\/10.1186\/s12886-022-02439-2","journal-title":"BMC Ophthalmol"},{"key":"4670_CR110","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1111\/aos.14891","volume":"100","author":"SA Minaker","year":"2022","unstructured":"Minaker SA, Mason RH, Lahaie Luna G et al (2022) Changes in aqueous and vitreous inflammatory cytokine levels in diabetic macular oedema: a systematic review and meta-analysis. Acta Ophthalmol 100:e53\u2013e70. https:\/\/doi.org\/10.1111\/aos.14891","journal-title":"Acta Ophthalmol"},{"key":"4670_CR111","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.ophtha.2004.11.045","volume":"112","author":"H Funatsu","year":"2005","unstructured":"Funatsu H, Yamashita H, Sakata K et al (2005) Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema. Ophthalmology 112:806\u2013816. https:\/\/doi.org\/10.1016\/j.ophtha.2004.11.045","journal-title":"Ophthalmology"},{"key":"4670_CR112","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-018-0874-6","author":"F Yenihayat","year":"2018","unstructured":"Yenihayat F, \u00d6zkan B, Kasap M et al (2018) Vitreous IL-8 and VEGF levels in diabetic macular edema with or without subretinal fluid. Int Ophthalmol. https:\/\/doi.org\/10.1007\/s10792-018-0874-6","journal-title":"Int Ophthalmol"},{"key":"4670_CR113","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/sj.eye.6702498","volume":"22","author":"H Noma","year":"2008","unstructured":"Noma H, Funatsu H, Yamasaki M et al (2008) Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. Eye 22:42\u201348. https:\/\/doi.org\/10.1038\/sj.eye.6702498","journal-title":"Eye"},{"key":"4670_CR114","doi-asserted-by":"publisher","first-page":"e8158","DOI":"10.1371\/journal.pone.0008158","volume":"4","author":"T Yoshimura","year":"2009","unstructured":"Yoshimura T, Sonoda K-HH, Sugahara M et al (2009) Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases. PLoS ONE 4:e8158. https:\/\/doi.org\/10.1371\/journal.pone.0008158","journal-title":"PLoS ONE"},{"key":"4670_CR115","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s10384-017-0525-x","volume":"61","author":"K Kimura","year":"2017","unstructured":"Kimura K, Orita T, Kobayashi Y et al (2017) Concentration of acute phase factors in vitreous fluid in diabetic macular edema. Jpn J Ophthalmol 61:479\u2013483. https:\/\/doi.org\/10.1007\/s10384-017-0525-x","journal-title":"Jpn J Ophthalmol"},{"key":"4670_CR116","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.preteyeres.2013.07.003","volume":"37","author":"D Ardeljan","year":"2013","unstructured":"Ardeljan D, Chan CC (2013) Aging is not a disease: distinguishing age-related macular degeneration from aging. Prog Retin Eye Res 37:68\u201389. https:\/\/doi.org\/10.1016\/j.preteyeres.2013.07.003","journal-title":"Prog Retin Eye Res"},{"key":"4670_CR117","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/S0140-6736(12)60282-7","volume":"379","author":"LS Lim","year":"2012","unstructured":"Lim LS, Mitchell P, Seddon JM et al (2012) Age-related macular degeneration. Lancet 379:1728\u20131738. https:\/\/doi.org\/10.1016\/S0140-6736(12)60282-7","journal-title":"Lancet"},{"key":"4670_CR118","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong WL, Su X, Li X et al (2014) Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Heal 2:e106\u2013e116. https:\/\/doi.org\/10.1016\/S2214-109X(13)70145-1","journal-title":"Lancet Glob Heal"},{"key":"4670_CR119","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.ophtha.2011.09.027","volume":"119","author":"AR Rudnicka","year":"2012","unstructured":"Rudnicka AR, Jarrar Z, Wormald R et al (2012) Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry: a meta-analysis. Ophthalmology 119:571\u2013580. https:\/\/doi.org\/10.1016\/j.ophtha.2011.09.027","journal-title":"Ophthalmology"},{"key":"4670_CR120","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.ophtha.2004.10.047","volume":"112","author":"Age-Related Eye Disease Study Research Group","year":"2005","unstructured":"Age-Related Eye Disease Study Research Group (2005) Risk factors for the incidence of advanced age-related macular degeneration in the age-related eye disease study (AREDS). Ophthalmology 112:533-539.e1. https:\/\/doi.org\/10.1016\/j.ophtha.2004.10.047","journal-title":"Ophthalmology"},{"key":"4670_CR121","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.preteyeres.2016.04.003","volume":"54","author":"NG Lambert","year":"2016","unstructured":"Lambert NG, ElShelmani H, Singh MK et al (2016) Risk factors and biomarkers of age-related macular degeneration. Prog Retin Eye Res 54:64\u2013102. https:\/\/doi.org\/10.1016\/j.preteyeres.2016.04.003","journal-title":"Prog Retin Eye Res"},{"key":"4670_CR122","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/nri3459","volume":"13","author":"J Ambati","year":"2013","unstructured":"Ambati J, Atkinson JP, Gelfand BD (2013) Immunology of age-related macular degeneration. Nat Rev Immunol 13:438\u2013451. https:\/\/doi.org\/10.1038\/nri3459","journal-title":"Nat Rev Immunol"},{"key":"4670_CR123","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1056\/NEJMcp2102061","volume":"385","author":"RS Apte","year":"2021","unstructured":"Apte RS (2021) Age-related macular degeneration. N Engl J Med 385:539\u2013547. https:\/\/doi.org\/10.1056\/NEJMcp2102061","journal-title":"N Engl J Med"},{"key":"4670_CR124","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1056\/NEJMra0801537","volume":"358","author":"RD Jager","year":"2008","unstructured":"Jager RD, Mieler WF, Miller JW (2008) Age-related macular degeneration. N Engl J Med 358:2606\u20132617. https:\/\/doi.org\/10.1056\/NEJMra0801537","journal-title":"N Engl J Med"},{"key":"4670_CR125","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.mcna.2021.01.003","volume":"105","author":"CJ Thomas","year":"2021","unstructured":"Thomas CJ, Mirza RG, Gill MK (2021) Age-related macular degeneration. Med Clin North Am 105:473\u2013491. https:\/\/doi.org\/10.1016\/j.mcna.2021.01.003","journal-title":"Med Clin North Am"},{"key":"4670_CR126","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1001\/archopht.123.11.1484","volume":"123","author":"Age-Related Eye Disease Study Research Group","year":"2005","unstructured":"Age-Related Eye Disease Study Research Group (2005) The age-related eye disease study severity scale for age-related macular degeneration. Arch Ophthalmol 123:1484. https:\/\/doi.org\/10.1001\/archopht.123.11.1484","journal-title":"Arch Ophthalmol"},{"key":"4670_CR127","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/S0140-6736(08)61759-6","volume":"372","author":"HR Coleman","year":"2008","unstructured":"Coleman HR, Chan C-C, Ferris FL, Chew EY (2008) Age-related macular degeneration. Lancet 372:1835\u20131845. https:\/\/doi.org\/10.1016\/S0140-6736(08)61759-6","journal-title":"Lancet"},{"key":"4670_CR128","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.ophtha.2007.08.030","volume":"115","author":"ML Klein","year":"2008","unstructured":"Klein ML, Ferris FL, Armstrong J et al (2008) Retinal precursors and the development of geographic atrophy in age-related macular degeneration. Ophthalmology 115:1026\u20131031. https:\/\/doi.org\/10.1016\/j.ophtha.2007.08.030","journal-title":"Ophthalmology"},{"key":"4670_CR129","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.yaoo.2016.03.018","volume":"1","author":"S Richer","year":"2016","unstructured":"Richer S, Ulanski L, Popenko NA et al (2016) Age-related macular degeneration beyond the age-related eye disease study II. Adv Ophthalmol Optom 1:335\u2013369. https:\/\/doi.org\/10.1016\/j.yaoo.2016.03.018","journal-title":"Adv Ophthalmol Optom"},{"key":"4670_CR130","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1001\/archopht.119.10.1417","volume":"119","author":"Age-Related Eye Disease Study Research Group","year":"2001","unstructured":"Age-Related Eye Disease Study Research Group (2001) A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss. Arch Ophthalmol 119:1417\u20131436. https:\/\/doi.org\/10.1001\/archopht.119.10.1417","journal-title":"Arch Ophthalmol"},{"key":"4670_CR131","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1001\/archopht.124.7.995","volume":"124","author":"JM Seddon","year":"2006","unstructured":"Seddon JM (2006) Cigarette smoking, fish consumption, omega-3 fatty acid intake, and associations with age-related macular degeneration. Arch Ophthalmol 124:995\u20131001. https:\/\/doi.org\/10.1001\/archopht.124.7.995","journal-title":"Arch Ophthalmol"},{"key":"4670_CR132","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0227048","volume":"14","author":"L Feng","year":"2019","unstructured":"Feng L, Nie K, Jiang H, Fan W (2019) Effects of lutein supplementation in age-related macular degeneration. PLoS ONE 14:1\u201313. https:\/\/doi.org\/10.1371\/journal.pone.0227048","journal-title":"PLoS ONE"},{"key":"4670_CR133","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1001\/jama.2015.9677","volume":"314","author":"EY Chew","year":"2015","unstructured":"Chew EY, Clemons TE, Agr\u00f3n E et al (2015) Effect of omega-3 fatty acids, lutein\/zeaxanthin, or other nutrient supplementation on cognitive function. JAMA 314:791. https:\/\/doi.org\/10.1001\/jama.2015.9677","journal-title":"JAMA"},{"key":"4670_CR134","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/antiox10081255","volume":"10","author":"DW Lem","year":"2021","unstructured":"Lem DW, Davey PG, Gierhart DL, Rosen RB (2021) A systematic review of carotenoids in the management of age-related macular degeneration. Antioxidants 10:1\u201337. https:\/\/doi.org\/10.3390\/antiox10081255","journal-title":"Antioxidants"},{"key":"4670_CR135","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1136\/bjophthalmol-2020-318452","volume":"106","author":"TA Cabral De Guimaraes","year":"2022","unstructured":"Cabral De Guimaraes TA, Daich Varela M, Georgiou M, Michaelides M (2022) Treatments for dry age-related macular degeneration: therapeutic avenues, clinical trials and future directions. Br J Ophthalmol 106:297\u2013304. https:\/\/doi.org\/10.1136\/bjophthalmol-2020-318452","journal-title":"Br J Ophthalmol"},{"key":"4670_CR136","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1111\/bph.15459","volume":"179","author":"CN Thomas","year":"2022","unstructured":"Thomas CN, Sim DA, Lee WH et al (2022) Emerging therapies and their delivery for treating age-related macular degeneration. Br J Pharmacol 179:1908\u20131937. https:\/\/doi.org\/10.1111\/bph.15459","journal-title":"Br J Pharmacol"},{"key":"4670_CR137","doi-asserted-by":"publisher","unstructured":"Stern JH, Tian Y, Funderburgh J, et al (2018) Regenerating Eye Tissues to Preserve and Restore Vision. Cell Stem Cell 22:834\u2013849. DOI: https:\/\/doi.org\/10.1016\/j.stem.2018.05.013","DOI":"10.1016\/j.stem.2018.05.013"},{"key":"4670_CR138","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1093\/stcltm\/szac001","volume":"11","author":"LJ Rizzolo","year":"2022","unstructured":"Rizzolo LJ, Nasonkin IO, Adelman RA (2022) Retinal cell transplantation, biomaterials, and in vitro models for developing next-generation therapies of age-related macular degeneration. Stem Cells Transl Med 11:269\u2013281. https:\/\/doi.org\/10.1093\/stcltm\/szac001","journal-title":"Stem Cells Transl Med"},{"key":"4670_CR139","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013154.pub2","author":"JL Yeong","year":"2020","unstructured":"Yeong JL, Loveman E, Colquitt JL et al (2020) Visual cycle modulators versus placebo or observation for the prevention and treatment of geographic atrophy due to age-related macular degeneration. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD013154.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"4670_CR140","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1167\/iovs.13-11650","volume":"54","author":"WT Wong","year":"2013","unstructured":"Wong WT, Dresner S, Forooghian F et al (2013) Treatment of geographic atrophy with subconjunctival sirolimus: results of a phase I\/II clinical trial. Investig Opthalmology Vis Sci 54:2941. https:\/\/doi.org\/10.1167\/iovs.13-11650","journal-title":"Investig Opthalmology Vis Sci"},{"key":"4670_CR141","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3928\/23258160-20210528-05","volume":"52","author":"DS Boyer","year":"2021","unstructured":"Boyer DS, Gonzalez VH, Kunimoto DY et al (2021) Safety and efficacy of intravitreal risuteganib for non-exudative AMD: a multicenter, phase 2a, randomized, clinical trial. Ophthalmic Surgery, Lasers Imaging Retin 52:327\u2013335. https:\/\/doi.org\/10.3928\/23258160-20210528-05","journal-title":"Ophthalmic Surgery, Lasers Imaging Retin"},{"key":"4670_CR142","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.2147\/DDDT.S206355","volume":"13","author":"J Wu","year":"2019","unstructured":"Wu J, Sun X (2019) Complement system and age-related macular degeneration: drugs and challenges. Drug Des Devel Ther 13:2413\u20132425. https:\/\/doi.org\/10.2147\/DDDT.S206355","journal-title":"Drug Des Devel Ther"},{"key":"4670_CR143","doi-asserted-by":"publisher","first-page":"7484","DOI":"10.1167\/iovs.12-9970","volume":"53","author":"K Kauper","year":"2012","unstructured":"Kauper K, McGovern C, Sherman S et al (2012) Two-year intraocular delivery of ciliary neurotrophic factor by encapsulated cell technology implants in patients with chronic retinal degenerative diseases. Investig Opthalmology Vis Sci 53:7484. https:\/\/doi.org\/10.1167\/iovs.12-9970","journal-title":"Investig Opthalmology Vis Sci"},{"key":"4670_CR144","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1007\/s00417-021-05164-6","volume":"259","author":"A Sharma","year":"2021","unstructured":"Sharma A, Parachuri N, Kumar N et al (2021) Terms non-exudative and non-neovascular: awaiting entry at the doors of AMD reclassification. Graefe\u2019s Arch Clin Exp Ophthalmol 259:1381\u20131383. https:\/\/doi.org\/10.1007\/s00417-021-05164-6","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"4670_CR145","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","volume":"127","author":"RF Spaide","year":"2020","unstructured":"Spaide RF, Jaffe GJ, Sarraf D et al (2020) Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on neovascular age-related macular degeneration nomenclature study group. Ophthalmology 127:616\u2013636. https:\/\/doi.org\/10.1016\/j.ophtha.2019.11.004","journal-title":"Ophthalmology"},{"key":"4670_CR146","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3390\/jcm4020343","volume":"4","author":"Y Yonekawa","year":"2015","unstructured":"Yonekawa Y, Miller J, Kim I (2015) Age-related macular degeneration: advances in management and diagnosis. J Clin Med 4:343\u2013359. https:\/\/doi.org\/10.3390\/jcm4020343","journal-title":"J Clin Med"},{"key":"4670_CR147","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.survophthal.2017.01.008","volume":"62","author":"ASH Tsai","year":"2017","unstructured":"Tsai ASH, Cheung N, Gan ATL et al (2017) Retinal angiomatous proliferation. Surv Ophthalmol 62:462\u2013492. https:\/\/doi.org\/10.1016\/j.survophthal.2017.01.008","journal-title":"Surv Ophthalmol"},{"key":"4670_CR148","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1097\/IAE.0b013e31823f9b3b","volume":"32","author":"LA Yannuzzi","year":"2012","unstructured":"Yannuzzi LA, Negr\u00e3o S, Iida T et al (2012) Retinal angiomatous proliferation in age\u2013related macular degeneration. Retina 32:416\u2013434. https:\/\/doi.org\/10.1097\/IAE.0b013e31823f9b3b","journal-title":"Retina"},{"key":"4670_CR149","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/bmb\/ldt004","volume":"105","author":"S Sivaprasad","year":"2013","unstructured":"Sivaprasad S, Hykin P (2013) What is new in the management of wet age-related macular degeneration? Br Med Bull 105:201\u2013211","journal-title":"Br Med Bull"},{"key":"4670_CR150","doi-asserted-by":"crossref","unstructured":"Chaili S, D. Adrean S (2020) Management strategies and visual results for the treatment of neovascular age-related macular degeneration. In: Visual impairment and blindness\u2014what we know and what we have to know. IntechOpen, p 13","DOI":"10.5772\/intechopen.81466"},{"key":"4670_CR151","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C et al (2022) Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet 399:729\u2013740. https:\/\/doi.org\/10.1016\/S0140-6736(22)00010-1","journal-title":"Lancet"},{"key":"4670_CR152","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.3390\/ijms23052592","volume":"23","author":"AR Fernandes","year":"2022","unstructured":"Fernandes AR, Zieli\u0144ska A, Sanchez-Lopez E et al (2022) Exudative versus nonexudative age-related macular degeneration: physiopathology and treatment options. Int J Mol Sci 23:2592. https:\/\/doi.org\/10.3390\/ijms23052592","journal-title":"Int J Mol Sci"},{"key":"4670_CR153","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1136\/bjophthalmol-2020-316195","volume":"105","author":"TAC De Guimaraes","year":"2021","unstructured":"De Guimaraes TAC, Georgiou M, Bainbridge JWB, Michaelides M (2021) Gene therapy for neovascular age-related macular degeneration: rationale, clinical trials and future directions. Br J Ophthalmol 105:151\u2013157. https:\/\/doi.org\/10.1136\/bjophthalmol-2020-316195","journal-title":"Br J Ophthalmol"},{"key":"4670_CR154","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1146\/annurev-genom-090413-025610","volume":"15","author":"LG Fritsche","year":"2014","unstructured":"Fritsche LG, Fariss RN, Stambolian D et al (2014) Age-related macular degeneration: genetics and biology coming together. Annu Rev Genomics Hum Genet 15:151\u2013171. https:\/\/doi.org\/10.1146\/annurev-genom-090413-025610","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"4670_CR155","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/8374647","volume":"2018","author":"LF Hern\u00e1ndez-Zimbr\u00f3n","year":"2018","unstructured":"Hern\u00e1ndez-Zimbr\u00f3n LF, Zamora-Alvarado R, Ochoa-De la Paz L et al (2018) Age-related macular degeneration: new paradigms for treatment and management of AMD. Oxid Med Cell Longev 2018:1\u201314. https:\/\/doi.org\/10.1155\/2018\/8374647","journal-title":"Oxid Med Cell Longev"},{"key":"4670_CR156","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0096895","volume":"9","author":"MJ Koss","year":"2014","unstructured":"Koss MJ, Hoffmann J, Nguyen N et al (2014) Proteomics of vitreous humor of patients with exudative age-related macular degeneration. PLoS ONE 9:1\u201311. https:\/\/doi.org\/10.1371\/journal.pone.0096895","journal-title":"PLoS ONE"},{"key":"4670_CR157","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.exer.2016.01.001","volume":"146","author":"M Nobl","year":"2016","unstructured":"Nobl M, Reich M, Dacheva I et al (2016) Proteomics of vitreous in neovascular age-related macular degeneration. Exp Eye Res 146:107\u2013117. https:\/\/doi.org\/10.1016\/j.exer.2016.01.001","journal-title":"Exp Eye Res"},{"key":"4670_CR158","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.phrs.2015.11.027","volume":"103","author":"M Amadio","year":"2016","unstructured":"Amadio M, Govoni S, Pascale A (2016) Targeting VEGF in eye neovascularization: What\u2019s new?: A comprehensive review on current therapies and oligonucleotide-based interventions under development. Pharmacol Res 103:253\u2013269. https:\/\/doi.org\/10.1016\/j.phrs.2015.11.027","journal-title":"Pharmacol Res"},{"key":"4670_CR159","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1016\/j.ophtha.2009.05.039","volume":"116","author":"M Funk","year":"2009","unstructured":"Funk M, Karl D, Georgopoulos M et al (2009) Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab. Ophthalmology 116:2393\u20132399. https:\/\/doi.org\/10.1016\/j.ophtha.2009.05.039","journal-title":"Ophthalmology"},{"key":"4670_CR160","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/S0002-9394(02)01549-0","volume":"134","author":"NM Holekamp","year":"2002","unstructured":"Holekamp NM, Bouck N, Volpert O (2002) Pigment epithelium-derived factor is deficient in the vitreous of patients with choroidal neovascularization due to age-related macular degeneration. Am J Ophthalmol 134:220\u2013227. https:\/\/doi.org\/10.1016\/S0002-9394(02)01549-0","journal-title":"Am J Ophthalmol"},{"key":"4670_CR161","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.ajo.2003.11.015","volume":"137","author":"EJ Duh","year":"2004","unstructured":"Duh EJ, Yang HS, Haller JA et al (2004) Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor: implications for ocular angiogenesis. Am J Ophthalmol 137:668\u2013674. https:\/\/doi.org\/10.1016\/j.ajo.2003.11.015","journal-title":"Am J Ophthalmol"},{"key":"4670_CR162","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2011\/459251","volume":"2011","author":"MJ Koss","year":"2011","unstructured":"Koss MJ, Pfister M, Koch FH (2011) Inflammatory and angiogenic protein detection in the human vitreous: cytometric bead assay. J Ophthalmol 2011:1\u20134. https:\/\/doi.org\/10.1155\/2011\/459251","journal-title":"J Ophthalmol"},{"key":"4670_CR163","doi-asserted-by":"publisher","first-page":"e0125150","DOI":"10.1371\/journal.pone.0125150","volume":"10","author":"M Zhao","year":"2015","unstructured":"Zhao M, Bai Y, Xie W et al (2015) Interleukin-1\u03b2 level is increased in vitreous of patients with neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV). PLoS ONE 10:e0125150. https:\/\/doi.org\/10.1371\/journal.pone.0125150","journal-title":"PLoS ONE"},{"key":"4670_CR164","first-page":"1258","volume":"20","author":"Y Bai","year":"2014","unstructured":"Bai Y, Liang S, Yu W et al (2014) Semaphorin 3A blocks the formation of pathologic choroidal neovascularization induced by transforming growth factor beta. Mol Vis 20:1258\u20131270","journal-title":"Mol Vis"},{"key":"4670_CR165","first-page":"1658","volume":"18","author":"SM Ecker","year":"2012","unstructured":"Ecker SM, Pfahler SM, Hines JC et al (2012) Sequential in-office vitreous aspirates demonstrate vitreous matrix metalloproteinase-9 levels correlate with the amount of subretinal fluid in eyes with wet age-related macular degeneration. Mol Vis 18:1658\u20131667","journal-title":"Mol Vis"},{"key":"4670_CR166","doi-asserted-by":"publisher","first-page":"6628","DOI":"10.1167\/iovs.12-9587","volume":"53","author":"KM Loyet","year":"2012","unstructured":"Loyet KM, DeForge LE, Katschke KJ et al (2012) Activation of the alternative complement pathway in vitreous is controlled by genetics in age-related macular degeneration. Investig Ophthalmol Vis Sci 53:6628\u20136637. https:\/\/doi.org\/10.1167\/iovs.12-9587","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"4670_CR167","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/IIO.0000000000000258","volume":"59","author":"S Idrees","year":"2019","unstructured":"Idrees S, Sridhar J, Kuriyan AE (2019) Proliferative vitreoretinopathy: a review. Int Ophthalmol Clin 59:221\u2013240. https:\/\/doi.org\/10.1097\/IIO.0000000000000258","journal-title":"Int Ophthalmol Clin"},{"key":"4670_CR168","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.survophthal.2012.12.004","volume":"58","author":"JG Garweg","year":"2013","unstructured":"Garweg JG, Tappeiner C, Halberstadt M (2013) Pathophysiology of proliferative vitreoretinopathy in retinal detachment. Surv Ophthalmol 58:321\u2013329. https:\/\/doi.org\/10.1016\/j.survophthal.2012.12.004","journal-title":"Surv Ophthalmol"},{"key":"4670_CR169","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1080\/02713680490904142","volume":"30","author":"E Rodr\u00edguez De La R\u00faa","year":"2005","unstructured":"Rodr\u00edguez De La R\u00faa E, Pastor JC, Arag\u00f3n J et al (2005) Interaction between surgical procedure for repairing retinal detachment and clinical risk factors for proliferative vitreoretinopathy. Curr Eye Res 30:147\u2013153. https:\/\/doi.org\/10.1080\/02713680490904142","journal-title":"Curr Eye Res"},{"key":"4670_CR170","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/3-540-27152-X_8","volume-title":"Vitreo-retinal surgery","author":"CH Kon","year":"2005","unstructured":"Kon CH, Tranos P, Aylward GW (2005) Risk factors in proliferative vitreoretinopathy. Vitreo-retinal surgery. Springer-Verlag, Berlin\/Heidelberg, pp 121\u2013134"},{"key":"4670_CR171","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1016\/B978-1-4557-0737-9.00097-7","volume-title":"Retina","author":"P Wiedemann","year":"2013","unstructured":"Wiedemann P, Yandiev Y, Hui Y-N, Wang Y (2013) Pathogenesis of proliferative vitreoretinopathy. In: Ryan SJ, Hinton DR, Wiedemann P (eds) Retina, 5th edn. Elsevier, pp 1640\u20131646","edition":"5"},{"key":"4670_CR172","doi-asserted-by":"crossref","unstructured":"Kwon OW, Song JH, Roh MI, Song JH (2010) Retinal detachment and proliferative vitreoretinopathy. In: Retinal pharmacotherapy, 1st edn. Elsevier, pp 154\u2013162","DOI":"10.1159\/000438972"},{"key":"4670_CR173","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1167\/iovs.09-4725","volume":"51","author":"S Tamiya","year":"2010","unstructured":"Tamiya S, Liu LH, Kaplan HJ (2010) Epithelial-mesenchymal transition and proliferation of retinal pigment epithelial cells initiated upon loss of cell-cell contact. Investig Ophthalmol Vis Sci 51:2755\u20132763. https:\/\/doi.org\/10.1167\/iovs.09-4725","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"4670_CR174","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1167\/iovs.03-0518","volume":"46","author":"CS Sethi","year":"2005","unstructured":"Sethi CS, Lewis GP, Fisher SK et al (2005) Glial remodeling and neural plasticity in human retinal detachment with proliferative vitreoretinopathy. Investig Ophthalmol Vis Sci 46:329\u2013342. https:\/\/doi.org\/10.1167\/iovs.03-0518","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"4670_CR175","doi-asserted-by":"crossref","unstructured":"Guidry C (2010) Proliferative vitreoretinopathy. In: Ocular disease, 2nd edn. Elsevier, pp 612\u2013617","DOI":"10.1016\/B978-0-7020-2983-7.00078-4"},{"key":"4670_CR176","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.survophthal.2021.05.008","volume":"67","author":"MM Popovic","year":"2022","unstructured":"Popovic MM, Muni RH, Nichani P, Kertes PJ (2022) Pars plana vitrectomy, scleral buckle, and pneumatic retinopexy for the management of rhegmatogenous retinal detachment: a meta-analysis. Surv Ophthalmol 67:184\u2013196. https:\/\/doi.org\/10.1016\/j.survophthal.2021.05.008","journal-title":"Surv Ophthalmol"},{"key":"4670_CR177","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1080\/15569527.2019.1701000","volume":"39","author":"F Savur","year":"2020","unstructured":"Savur F, Aydemir O, \u0130lhan N (2020) The effect of infliximab and octreotide on cytokine levels experimental proliferative vitreoretinopathy. Cutan Ocul Toxicol 39:61\u201366. https:\/\/doi.org\/10.1080\/15569527.2019.1701000","journal-title":"Cutan Ocul Toxicol"},{"key":"4670_CR178","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1007\/s10792-017-0594-3","volume":"38","author":"MV Tikhonovich","year":"2018","unstructured":"Tikhonovich MV, Erdiakov AK, Gavrilova SA (2018) Nonsteroid anti-inflammatory therapy suppresses the development of proliferative vitreoretinopathy more effectively than a steroid one. Int Ophthalmol 38:1365\u20131378. https:\/\/doi.org\/10.1007\/s10792-017-0594-3","journal-title":"Int Ophthalmol"},{"key":"4670_CR179","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1186\/s13063-018-2761-x","volume":"19","author":"F Schaub","year":"2018","unstructured":"Schaub F, Hoerster R, Schiller P et al (2018) Prophylactic intravitreal 5-fluorouracil and heparin to prevent proliferative vitreoretinopathy in high-risk patients with retinal detachment: study protocol for a randomized controlled trial. Trials 19:384. https:\/\/doi.org\/10.1186\/s13063-018-2761-x","journal-title":"Trials"},{"key":"4670_CR180","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1159\/000500271","volume":"242","author":"R Nourinia","year":"2019","unstructured":"Nourinia R, Borna F, Rahimi A et al (2019) Repeated injection of methotrexate into silicone oil-filled eyes for grade c proliferative vitreoretinopathy: a pilot study. Ophthalmologica 242:113\u2013117. https:\/\/doi.org\/10.1159\/000500271","journal-title":"Ophthalmologica"},{"key":"4670_CR181","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/eye.2014.21","volume":"28","author":"K Ghasemi Falavarjani","year":"2014","unstructured":"Ghasemi Falavarjani K, Hashemi M, Modarres M, Hadavand Khani A (2014) Intrasilicone oil injection of bevacizumab at the end of retinal reattachment surgery for severe proliferative vitreoretinopathy. Eye 28:576\u2013580. https:\/\/doi.org\/10.1038\/eye.2014.21","journal-title":"Eye"},{"key":"4670_CR182","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1007\/s00417-018-4105-7","volume":"256","author":"AM Abdullatif","year":"2018","unstructured":"Abdullatif AM, Macky TA, Abdullatif MM et al (2018) Intravitreal decorin preventing proliferative vitreoretinopathy in perforating injuries: a pilot study. Graefe\u2019s Arch Clin Exp Ophthalmol 256:2473\u20132481. https:\/\/doi.org\/10.1007\/s00417-018-4105-7","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"4670_CR183","doi-asserted-by":"publisher","first-page":"132","DOI":"10.2353\/ajpath.2010.090604","volume":"177","author":"H Lei","year":"2010","unstructured":"Lei H, Velez G, Cui J et al (2010) N-acetylcysteine suppresses retinal detachment in an experimental model of proliferative vitreoretinopathy. Am J Pathol 177:132\u2013140. https:\/\/doi.org\/10.2353\/ajpath.2010.090604","journal-title":"Am J Pathol"},{"key":"4670_CR184","unstructured":"Aldeyra Therapeutics (2022) ClinicalTrials.gov Identifier: NCT04136366. The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy Stress. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04136366. Accessed 31 Jul 2022"},{"key":"4670_CR185","unstructured":"Zahra Rabbani Khah, Beheshti S (2020) ClinicalTrials.gov Identifier: NCT04482543. Repeated Methotrexate for Proliferative Vitreoretinopathy Grade C. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04482543. Accessed 31 Jul 2022"},{"key":"4670_CR186","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1007\/s00417-021-05206-z","volume":"259","author":"JA Roca","year":"2021","unstructured":"Roca JA, Yon-Mendoza A, Huam\u00e1n N, Wu L (2021) Adjunctive serial post-operative intravitreal methotrexate injections in the management of advanced proliferative vitreoretinopathy. Graefe\u2019s Arch Clin Exp Ophthalmol 259:2913\u20132917. https:\/\/doi.org\/10.1007\/s00417-021-05206-z","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"4670_CR187","first-page":"726","volume":"47","author":"G Chen","year":"2011","unstructured":"Chen G, Li T, Zheng Q et al (2011) Differential expression and significance of complement C4b and transthyretin in proliferative vitreoretinopathy. Chinese J Ophthalmol 47:726\u2013731","journal-title":"Chinese J Ophthalmol"},{"key":"4670_CR188","doi-asserted-by":"publisher","first-page":"3667","DOI":"10.1002\/pmic.200700824","volume":"8","author":"J Yu","year":"2008","unstructured":"Yu J, Liu F, Cui SJ et al (2008) Vitreous proteomic analysis of proliferative vitreoretinopathy. Proteomics 8:3667\u20133678. https:\/\/doi.org\/10.1002\/pmic.200700824","journal-title":"Proteomics"},{"key":"4670_CR189","doi-asserted-by":"publisher","first-page":"8146","DOI":"10.1167\/iovs.12-10079","volume":"53","author":"J Yu","year":"2012","unstructured":"Yu J, Peng R, Chen H et al (2012) Elucidation of the pathogenic mechanism of rhegmatogenous retinal detachment with proliferative vitreoretinopathy by proteomic analysis. Investig Ophthalmol Vis Sci 53:8146\u20138153. https:\/\/doi.org\/10.1167\/iovs.12-10079","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"4670_CR190","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/cxo.12088","volume":"97","author":"J Yu","year":"2014","unstructured":"Yu J, Peng R, Chen H et al (2014) Kininogen 1 and insulin-like growth factor binding protein 6: candidate serum biomarkers of proliferative vitreoretinopathy. Clin Exp Optom 97:72\u201379. https:\/\/doi.org\/10.1111\/cxo.12088","journal-title":"Clin Exp Optom"},{"key":"4670_CR191","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms19041157","volume":"19","author":"F Santos","year":"2018","unstructured":"Santos F, Gaspar L, Ciordia S et al (2018) iTRAQ quantitative proteomic analysis of vitreous from patients with retinal detachment. Int J Mol Sci 19:1\u201322. https:\/\/doi.org\/10.3390\/ijms19041157","journal-title":"Int J Mol Sci"},{"key":"4670_CR192","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-80005-w","volume":"11","author":"T \u00d6hman","year":"2021","unstructured":"\u00d6hman T, Gawriyski L, Miettinen S et al (2021) Molecular pathogenesis of rhegmatogenous retinal detachment. Sci Rep 11:1\u201315. https:\/\/doi.org\/10.1038\/s41598-020-80005-w","journal-title":"Sci Rep"},{"key":"4670_CR193","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1167\/iovs.06-1358","volume":"48","author":"S Banerjee","year":"2007","unstructured":"Banerjee S, Savant V, Scott RAHH et al (2007) Multiplex bead analysis of vitreous humor of patients with vitreoretinal disorders. Investig Ophthalmol Vis Sci 48:2203\u20132207. https:\/\/doi.org\/10.1167\/iovs.06-1358","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"4670_CR194","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ajo.2017.11.025","volume":"186","author":"CN Roybal","year":"2018","unstructured":"Roybal CN, Velez G, Toral MA et al (2018) Personalized proteomics in proliferative vitreoretinopathy implicate hematopoietic cell recruitment and mTOR as a therapeutic target. Am J Ophthalmol 186:152\u2013163. https:\/\/doi.org\/10.1016\/j.ajo.2017.11.025","journal-title":"Am J Ophthalmol"},{"key":"4670_CR195","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1097\/IAE.0b013e31826d350a","volume":"33","author":"EJ Wladis","year":"2013","unstructured":"Wladis EJ, Falk NS, Iglesias BV et al (2013) Analysis of the molecular biologic milieu of the vitreous in proliferative vitreoretinopathy. Retina 33:807\u2013811. https:\/\/doi.org\/10.1097\/IAE.0b013e31826d350a","journal-title":"Retina"},{"key":"4670_CR196","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.cyto.2011.02.001","volume":"54","author":"C Symeonidis","year":"2011","unstructured":"Symeonidis C, Papakonstantinou E, Androudi S et al (2011) Interleukin-6 and the matrix metalloproteinase response in the vitreous during proliferative vitreoretinopathy. Cytokine 54:212\u2013217. https:\/\/doi.org\/10.1016\/j.cyto.2011.02.001","journal-title":"Cytokine"},{"key":"4670_CR197","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1080\/09273940490518900","volume":"13","author":"H Canataroglu","year":"2005","unstructured":"Canataroglu H, Varinli I, Ozcan AA et al (2005) Interleukin (IL)-6, interleukin (IL)-8 levels and cellular composition of the vitreous humor in proliferative diabetic retinopathy, proliferative vitreoretinopathy, and traumatic proliferative vitreoretinopathy. Ocul Immunol Inflamm 13:375\u2013381. https:\/\/doi.org\/10.1080\/09273940490518900","journal-title":"Ocul Immunol Inflamm"},{"key":"4670_CR198","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1159\/000324200","volume":"47","author":"M Citirik","year":"2011","unstructured":"Citirik M, Kabatas EU, Batman C et al (2011) Vitreous vascular endothelial growth factor concentrations in proliferative diabetic retinopathy versus proliferative vitreoretinopathy. Ophthalmic Res 47:7\u201312. https:\/\/doi.org\/10.1159\/000324200","journal-title":"Ophthalmic Res"},{"key":"4670_CR199","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1159\/000086594","volume":"37","author":"M Sydorova","year":"2005","unstructured":"Sydorova M, Lee MS (2005) Vascular endothelial growth factor levels in vitreous and serum of patients with either proliferative diabetic retinopathy or proliferative vitreoretinopathy. Ophthalmic Res 37:188\u2013190. https:\/\/doi.org\/10.1159\/000086594","journal-title":"Ophthalmic Res"},{"key":"4670_CR200","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/815937","author":"SN Moysidis","year":"2012","unstructured":"Moysidis SN, Thanos A, Vavvas DG (2012) Mechanisms of inflammation in proliferative vitreoretinopathy: from bench to bedside. Mediators Inflamm. https:\/\/doi.org\/10.1155\/2012\/815937","journal-title":"Mediators Inflamm"},{"key":"4670_CR201","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/269787","author":"F Morescalchi","year":"2013","unstructured":"Morescalchi F, Duse S, Gambicorti E et al (2013) Proliferative vitreoretinopathy after eye injuries: an overexpression of growth factors and cytokines leading to a retinal keloid. Mediators Inflamm. https:\/\/doi.org\/10.1155\/2013\/269787","journal-title":"Mediators Inflamm"},{"key":"4670_CR202","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/IAE.0b013e31821800b9","volume":"32","author":"LJAG Ricker","year":"2012","unstructured":"Ricker LJAG, Dieudonn\u00e9 SC, Kessels AGH et al (2012) Antiangiogenic isoforms of vascular endothelial growth factor predominate in subretinal fluid of patients with rhegmatogenous retinal detachment and proliferative vitreoretinopathy. Retina 32:54\u201359. https:\/\/doi.org\/10.1097\/IAE.0b013e31821800b9","journal-title":"Retina"},{"key":"4670_CR203","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1093\/nar\/gky1131","volume":"47","author":"D Szklarczyk","year":"2019","unstructured":"Szklarczyk D, Gable AL, Lyon D et al (2019) STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res 47:607\u2013613. https:\/\/doi.org\/10.1093\/nar\/gky1131","journal-title":"Nucleic Acids Res"},{"key":"4670_CR204","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1096\/fj.03-1476fje","volume":"18","author":"AM Joussen","year":"2004","unstructured":"Joussen AM, Poulaki V, Le ML et al (2004) A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 18:1450\u20131452. https:\/\/doi.org\/10.1096\/fj.03-1476fje","journal-title":"FASEB J"},{"key":"4670_CR205","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.preteyeres.2011.05.002","volume":"30","author":"J Tang","year":"2011","unstructured":"Tang J, Kern TS (2011) Inflammation in diabetic retinopathy. Prog Retin Eye Res 30:343\u2013358. https:\/\/doi.org\/10.1016\/j.preteyeres.2011.05.002","journal-title":"Prog Retin Eye Res"},{"key":"4670_CR206","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1136\/bjo.86.4.363","volume":"86","author":"AP Adamis","year":"2002","unstructured":"Adamis AP (2002) Is diabetic retinopathy an inflammatory disease? Br J Ophthalmol 86:363\u2013365. https:\/\/doi.org\/10.1136\/bjo.86.4.363","journal-title":"Br J Ophthalmol"},{"key":"4670_CR207","doi-asserted-by":"publisher","first-page":"95103","DOI":"10.1155\/2007\/95103","volume":"2007","author":"TS Kern","year":"2007","unstructured":"Kern TS (2007) Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res 2007:95103. https:\/\/doi.org\/10.1155\/2007\/95103","journal-title":"Exp Diabetes Res"},{"key":"4670_CR208","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/348092","author":"SM Whitcup","year":"2013","unstructured":"Whitcup SM, Sodhi A, Atkinson JP et al (2013) The role of the immune response in age-related macular degeneration. Int J Inflam. https:\/\/doi.org\/10.1155\/2013\/348092","journal-title":"Int J Inflam"},{"key":"4670_CR209","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1167\/tvst.9.3.23","volume":"9","author":"R Chaudhary","year":"2020","unstructured":"Chaudhary R, Scott RAH, Wallace G et al (2020) Inflammatory and fibrogenic factors in proliferative vitreoretinopathy development. Transl Vis Sci Technol 9:1\u201317. https:\/\/doi.org\/10.1167\/tvst.9.3.23","journal-title":"Transl Vis Sci Technol"},{"key":"4670_CR210","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1007\/s10792-020-01325-4","volume":"40","author":"Y Dai","year":"2020","unstructured":"Dai Y, Dai C, Sun T (2020) Inflammatory mediators of proliferative vitreoretinopathy: hypothesis and review. Int Ophthalmol 40:1587\u20131601. https:\/\/doi.org\/10.1007\/s10792-020-01325-4","journal-title":"Int Ophthalmol"},{"key":"4670_CR211","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3934\/molsci.2016.2.196","volume":"3","author":"PX Shaw","year":"2016","unstructured":"Shaw PX, Stiles T, Douglas C et al (2016) Oxidative stress, innate immunity, and age-related macular degeneration. AIMS Mol Sci 3:196\u2013221. https:\/\/doi.org\/10.3934\/molsci.2016.2.196","journal-title":"AIMS Mol Sci"},{"key":"4670_CR212","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.25575","author":"M Capit\u00e3o","year":"2016","unstructured":"Capit\u00e3o M, Soares R (2016) Angiogenesis and inflammation crosstalk in diabetic retinopathy. J Cell Biochem. https:\/\/doi.org\/10.1002\/jcb.25575","journal-title":"J Cell Biochem"},{"key":"4670_CR213","doi-asserted-by":"publisher","first-page":"9672","DOI":"10.1038\/s41598-017-10124-4","volume":"7","author":"X Wang","year":"2017","unstructured":"Wang X, Ma W, Han S et al (2017) TGF-\u03b2 participates choroid neovascularization through Smad2\/3-VEGF\/TNF-\u03b1 signaling in mice with Laser-induced wet age-related macular degeneration. Sci Rep 7:9672. https:\/\/doi.org\/10.1038\/s41598-017-10124-4","journal-title":"Sci Rep"},{"key":"4670_CR214","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-016-0514-x","volume":"13","author":"N Fernando","year":"2016","unstructured":"Fernando N, Natoli R, Valter K et al (2016) The broad-spectrum chemokine inhibitor NR58-3.14.3 modulates macrophage-mediated inflammation in the diseased retina. J Neuroinflammation 13:1\u201314. https:\/\/doi.org\/10.1186\/s12974-016-0514-x","journal-title":"J Neuroinflammation"},{"key":"4670_CR215","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2019.01975","volume":"10","author":"K Rashid","year":"2019","unstructured":"Rashid K, Akhtar-Schaefer I, Langmann T (2019) Microglia in retinal degeneration. Front Immunol 10:1\u201319. https:\/\/doi.org\/10.3389\/fimmu.2019.01975","journal-title":"Front Immunol"},{"key":"4670_CR216","doi-asserted-by":"publisher","first-page":"105","DOI":"10.17925\/eor.2009.03.02.105","volume":"3","author":"J Cunha-Vaz","year":"2009","unstructured":"Cunha-Vaz J (2009) The blood-retinal barrier in retinal disease. Eur Ophthalmic Rev 3:105. https:\/\/doi.org\/10.17925\/eor.2009.03.02.105","journal-title":"Eur Ophthalmic Rev"},{"key":"4670_CR217","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1001\/archopht.1986.01050230123046","volume":"104","author":"PA Campochiaro","year":"1986","unstructured":"Campochiaro PA, Bryan JA, Conway BP, Jaccoma EH (1986) Intravitreal chemotactic and mitogenic activity: implication of blood-retinal barrier breakdown. Arch Ophthalmol 104:1685\u20131687. https:\/\/doi.org\/10.1001\/archopht.1986.01050230123046","journal-title":"Arch Ophthalmol"},{"key":"4670_CR218","doi-asserted-by":"publisher","first-page":"S140","DOI":"10.1038\/eye.1988.140","volume":"2","author":"C Gilbert","year":"1988","unstructured":"Gilbert C, Gilbert C, Unger W et al (1988) Inflammation and the formation of epiretinal membranes. Eye 2:S140\u2013S156. https:\/\/doi.org\/10.1038\/eye.1988.140","journal-title":"Eye"},{"key":"4670_CR219","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1038\/eye.2008.382","volume":"23","author":"AW Taylor","year":"2009","unstructured":"Taylor AW (2009) Ocular immune privilege. Eye 23:1885\u20131889. https:\/\/doi.org\/10.1038\/eye.2008.382","journal-title":"Eye"},{"key":"4670_CR220","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1159\/000491897","volume":"48","author":"J Xu","year":"2018","unstructured":"Xu J, Chen LJ, Yu J et al (2018) Involvement of advanced glycation end products in the pathogenesis of diabetic retinopathy. Cell Physiol Biochem 48:705\u2013717. https:\/\/doi.org\/10.1159\/000491897","journal-title":"Cell Physiol Biochem"},{"key":"4670_CR221","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.preteyeres.2008.09.003","volume":"27","author":"C Kaur","year":"2008","unstructured":"Kaur C, Foulds WS, Ling EA (2008) Blood-retinal barrier in hypoxic ischaemic conditions: basic concepts, clinical features and management. Prog Retin Eye Res 27:622\u2013647. https:\/\/doi.org\/10.1016\/j.preteyeres.2008.09.003","journal-title":"Prog Retin Eye Res"},{"key":"4670_CR222","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms19040942","volume":"19","author":"A R\u00fcbsam","year":"2018","unstructured":"R\u00fcbsam A, Parikh S, Fort PE (2018) Role of inflammation in diabetic retinopathy. Int J Mol Sci 19:1\u201331. https:\/\/doi.org\/10.3390\/ijms19040942","journal-title":"Int J Mol Sci"},{"key":"4670_CR223","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0108508","volume":"9","author":"S Rangasamy","year":"2014","unstructured":"Rangasamy S, McGuire PG, Nitta CF et al (2014) Chemokine mediated monocyte trafficking into the retina: role of inflammation in alteration of the blood-retinal barrier in diabetic retinopathy. PLoS ONE 9:1\u201310. https:\/\/doi.org\/10.1371\/journal.pone.0108508","journal-title":"PLoS ONE"},{"key":"4670_CR224","doi-asserted-by":"publisher","first-page":"5106","DOI":"10.1167\/iovs.06-0322","volume":"47","author":"NS Harhaj","year":"2006","unstructured":"Harhaj NS, Felinski EA, Wolpert EB et al (2006) VEGF activation of protein kinase C stimulates occludin phosphorylation and contributes to endothelial permeability. Investig Ophthalmol Vis Sci 47:5106\u20135115. https:\/\/doi.org\/10.1167\/iovs.06-0322","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"4670_CR225","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1016\/S0002-9440(10)65044-4","volume":"156","author":"K Miyamoto","year":"2000","unstructured":"Miyamoto K, Khosrof S, Bursell SE et al (2000) Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1). Am J Pathol 156:1733\u20131739. https:\/\/doi.org\/10.1016\/S0002-9440(10)65044-4","journal-title":"Am J Pathol"},{"key":"4670_CR226","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.2337\/db09-1606","volume":"59","author":"CA Aveleira","year":"2010","unstructured":"Aveleira CA, Lin CM, Abcouwer SF et al (2010) TNF-\u03b1 signals through PKC\u03b6\/NF-\u03baB to alter the tight junction complex and increase retinal endothelial cell permeability. Diabetes 59:2872\u20132882. https:\/\/doi.org\/10.2337\/db09-1606","journal-title":"Diabetes"},{"key":"4670_CR227","first-page":"329","volume":"150","author":"SD Bamforth","year":"1997","unstructured":"Bamforth SD, Lightman SL, Greenwood J (1997) Interleukin-1\u03b2-induced disruption of the retinal vascular barrier of the central nervous system is mediated through leukocyte recruitment and histamine. Am J Pathol 150:329\u2013340","journal-title":"Am J Pathol"},{"key":"4670_CR228","doi-asserted-by":"publisher","first-page":"22961","DOI":"10.1074\/jbc.M109.014787","volume":"284","author":"V Haurigot","year":"2009","unstructured":"Haurigot V, Villacampa P, Ribera A et al (2009) Increased intraocular insulin-like growth factor-I triggers blood-retinal barrier breakdown. J Biol Chem 284:22961\u201322969. https:\/\/doi.org\/10.1074\/jbc.M109.014787","journal-title":"J Biol Chem"},{"key":"4670_CR229","first-page":"1808","volume":"40","author":"M Lu","year":"1999","unstructured":"Lu M, Perez VL, Ma N et al (1999) VEGF increases retinal vascular ICAM-1 expression in vivo. Invest Ophthalmol Vis Sci 40:1808\u20131812","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4670_CR230","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.2337\/db06-1694","volume":"56","author":"D Navaratna","year":"2007","unstructured":"Navaratna D, McGuire PG, Menicucci G, Das A (2007) Proteolytic degradation of VE-cadherin alters the blood-retinal barrier in diabetes. Diabetes 56:2380\u20132387. https:\/\/doi.org\/10.2337\/db06-1694","journal-title":"Diabetes"},{"key":"4670_CR231","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/labinvest.3700251","volume":"85","author":"SJ Giebel","year":"2005","unstructured":"Giebel SJ, Menicucci G, McGuire PG, Das A (2005) Matrix metalloproteinases in early diabetic retinopathy and their role in alternation of the blood-retinal barrier. Lab Investig 85:597\u2013607. https:\/\/doi.org\/10.1038\/labinvest.3700251","journal-title":"Lab Investig"},{"key":"4670_CR232","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1080\/02713683.2017.1410180","volume":"43","author":"AP Da Cunha","year":"2018","unstructured":"Da Cunha AP, Zhang Q, Prentiss M et al (2018) The hierarchy of proinflammatory cytokines in ocular inflammation. Curr Eye Res 43:553\u2013565. https:\/\/doi.org\/10.1080\/02713683.2017.1410180","journal-title":"Curr Eye Res"},{"key":"4670_CR233","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.yexcr.2014.08.040","volume":"331","author":"X Liu","year":"2015","unstructured":"Liu X, Ye F, Xiong H et al (2015) IL-1\u03b2 Induces IL-6 production in retinal M\u00fcller cells predominantly through the activation of P38 MAPK\/NF-\u03baB signaling pathway. Exp Cell Res 331:223\u2013231. https:\/\/doi.org\/10.1016\/j.yexcr.2014.08.040","journal-title":"Exp Cell Res"},{"key":"4670_CR234","doi-asserted-by":"publisher","first-page":"20388","DOI":"10.1073\/pnas.0908698106","volume":"106","author":"SS Iyer","year":"2009","unstructured":"Iyer SS, Pulskens WP, Sadler JJ et al (2009) Necrotic cells trigger a sterile inflammatory response through the Nlrp3 inflammasome. Proc Natl Acad Sci USA 106:20388\u201320393. https:\/\/doi.org\/10.1073\/pnas.0908698106","journal-title":"Proc Natl Acad Sci USA"},{"key":"4670_CR235","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/ni.1636","volume":"9","author":"A Halle","year":"2008","unstructured":"Halle A, Hornung V, Petzold GC et al (2008) The NALP3 inflammasome is involved in the innate immune response to amyloid-\u03b2. Nat Immunol 9:857\u2013865. https:\/\/doi.org\/10.1038\/ni.1636","journal-title":"Nat Immunol"},{"key":"4670_CR236","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1167\/iovs.12-10849","volume":"54","author":"RT Liu","year":"2013","unstructured":"Liu RT, Gao J, Cao S et al (2013) Inflammatory mediators induced by amyloid-beta in the retina and RPE in vivo: implications for inflammasome activation in age-related macular degeneration. Investig Ophthalmol Vis Sci 54:2225\u20132237. https:\/\/doi.org\/10.1167\/iovs.12-10849","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"4670_CR237","first-page":"1156","volume":"22","author":"RK Kutty","year":"2016","unstructured":"Kutty RK, Samuel W, Boyce K et al (2016) Proinflammatory cytokines decrease the expression of genes critical for RPE function. Mol Vis 22:1156\u20131168","journal-title":"Mol Vis"},{"key":"4670_CR238","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2019.01618","volume":"10","author":"Y Wooff","year":"2019","unstructured":"Wooff Y, Man SM, Aggio-Bruce R et al (2019) IL-1 family members mediate cell death, inflammation and angiogenesis in retinal degenerative diseases. Front Immunol 10:1\u201321. https:\/\/doi.org\/10.3389\/fimmu.2019.01618","journal-title":"Front Immunol"},{"key":"4670_CR239","doi-asserted-by":"publisher","DOI":"10.1186\/s12348-019-0182-y","author":"S Karkhur","year":"2019","unstructured":"Karkhur S, Hasanreisoglu M, Vigil E et al (2019) Interleukin-6 inhibition in the management of non-infectious uveitis and beyond. J Ophthalmic Inflamm Infect. https:\/\/doi.org\/10.1186\/s12348-019-0182-y","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"4670_CR240","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1167\/iovs.04-0860","volume":"46","author":"C Gerhardinger","year":"2005","unstructured":"Gerhardinger C, Costa MB, Coulombe MC et al (2005) Expression of acute-phase response proteins in retinal M\u00fcller cells in diabetes. Investig Ophthalmol Vis Sci 46:349\u2013357. https:\/\/doi.org\/10.1167\/iovs.04-0860","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"4670_CR241","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/0717-6287-47-58","volume":"47","author":"G Ortiz","year":"2014","unstructured":"Ortiz G, Salica JP, Chuluyan EH, Gallo JE (2014) Diabetic retinopathy: could the alpha-1 antitrypsin be a therapeutic option? Biol Res 47:1\u20139. https:\/\/doi.org\/10.1186\/0717-6287-47-58","journal-title":"Biol Res"},{"key":"4670_CR242","doi-asserted-by":"publisher","first-page":"AMD83","DOI":"10.1167\/iovs.18-23893","volume":"59","author":"DA Copland","year":"2018","unstructured":"Copland DA, Theodoropoulou S, Liu J, Dick AD (2018) A perspective of AMD through the eyes of immunology. Investig Ophthalmol Vis Sci 59:AMD83\u2013AMD92. https:\/\/doi.org\/10.1167\/iovs.18-23893","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"4670_CR243","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.cyto.2017.10.014","volume":"106","author":"A Blum","year":"2018","unstructured":"Blum A, Pastukh N, Socea D, Jabaly H (2018) Levels of adhesion molecules in peripheral blood correlat with stages of diabetic retinopathy and may serve as bio markers for microvascular complications. Cytokine 106:76\u201379. https:\/\/doi.org\/10.1016\/j.cyto.2017.10.014","journal-title":"Cytokine"},{"key":"4670_CR244","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/nri2852","volume":"10","author":"L Sorokin","year":"2010","unstructured":"Sorokin L (2010) The impact of the extracellular matrix on inflammation. Nat Rev Immunol 10:712\u2013723. https:\/\/doi.org\/10.1038\/nri2852","journal-title":"Nat Rev Immunol"},{"key":"4670_CR245","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.preteyeres.2012.08.004","volume":"32","author":"AS Bharadwaj","year":"2013","unstructured":"Bharadwaj AS, Appukuttan B, Wilmarth PA et al (2013) Role of the retinal vascular endothelial cell in ocular disease. Prog Retin Eye Res 32:102\u2013180. https:\/\/doi.org\/10.1016\/j.preteyeres.2012.08.004","journal-title":"Prog Retin Eye Res"},{"key":"4670_CR246","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1076\/ceyr.19.3.219.5314","volume":"19","author":"GR Barile","year":"1999","unstructured":"Barile GR, Chang SS, Park LS et al (1999) Soluble cellular adhesion molecules in proliferative vitreoretinopathy and proliferative diabetic retinopathy. Curr Eye Res 19:219\u2013227. https:\/\/doi.org\/10.1076\/ceyr.19.3.219.5314","journal-title":"Curr Eye Res"},{"key":"4670_CR247","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1136\/bjo.83.8.953","volume":"83","author":"GA Limb","year":"1999","unstructured":"Limb GA, Chignell AH (1999) Vitreous levels of intercellular adhesion molecule 1 (ICAM-1) as a risk indicator of proliferative vitreoretinopathy. Br J Ophthalmol 83:953\u2013956. https:\/\/doi.org\/10.1136\/bjo.83.8.953","journal-title":"Br J Ophthalmol"},{"key":"4670_CR248","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnagi.2018.00015","volume":"10","author":"R Mukai","year":"2018","unstructured":"Mukai R, Okunuki Y, Husain D et al (2018) The complement system is critical in maintaining retinal integrity during aging. Front Aging Neurosci 10:1\u201312. https:\/\/doi.org\/10.3389\/fnagi.2018.00015","journal-title":"Front Aging Neurosci"},{"key":"4670_CR249","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00281-017-0649-6","volume":"40","author":"SJ Clark","year":"2018","unstructured":"Clark SJ, Bishop PN (2018) The eye as a complement dysregulation hotspot. Semin Immunopathol 40:65\u201374. https:\/\/doi.org\/10.1007\/s00281-017-0649-6","journal-title":"Semin Immunopathol"},{"key":"4670_CR250","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.preteyeres.2017.09.001","volume":"62","author":"CB Toomey","year":"2018","unstructured":"Toomey CB, Johnson LV, Bowes Rickman C (2018) Complement factor H in AMD: bridging genetic associations and pathobiology. Prog Retin Eye Res 62:38\u201357. https:\/\/doi.org\/10.1016\/j.preteyeres.2017.09.001","journal-title":"Prog Retin Eye Res"},{"key":"4670_CR251","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.preteyeres.2014.11.005","volume":"45","author":"SS Whitmore","year":"2015","unstructured":"Whitmore SS, Sohn EH, Chirco KR et al (2015) Complement activation and choriocapillaris loss in early AMD: implications for pathophysiology and therapy. Prog Retin Eye Res 45:1\u201329. https:\/\/doi.org\/10.1016\/j.preteyeres.2014.11.005","journal-title":"Prog Retin Eye Res"},{"key":"4670_CR252","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1016\/j.ajpath.2014.07.017","volume":"184","author":"RF Mullins","year":"2014","unstructured":"Mullins RF, Schoo DP, Sohn EH et al (2014) The membrane attack complex in aging human choriocapillaris: relationship to macular degeneration and choroidal thinning. Am J Pathol 184:3142\u20133153. https:\/\/doi.org\/10.1016\/j.ajpath.2014.07.017","journal-title":"Am J Pathol"},{"key":"4670_CR253","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15252\/emmm.201708259","volume":"10","author":"I Akhtar-Sch\u00e4fer","year":"2018","unstructured":"Akhtar-Sch\u00e4fer I, Wang L, Krohne TU et al (2018) Modulation of three key innate immune pathways for the most common retinal degenerative diseases. EMBO Mol Med 10:1\u201327. https:\/\/doi.org\/10.15252\/emmm.201708259","journal-title":"EMBO Mol Med"},{"key":"4670_CR254","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/1313027","author":"MM Yang","year":"2016","unstructured":"Yang MM, Wang J, Ren H et al (2016) Genetic investigation of complement pathway genes in type 2 diabetic retinopathy: an inflammatory perspective. Mediators Inflamm. https:\/\/doi.org\/10.1155\/2016\/1313027","journal-title":"Mediators Inflamm"},{"key":"4670_CR255","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2020.00154","volume":"11","author":"S Shahulhameed","year":"2020","unstructured":"Shahulhameed S, Vishwakarma S, Chhablani J et al (2020) A systematic investigation on complement pathway activation in diabetic retinopathy. Front Immunol 11:1\u201314. https:\/\/doi.org\/10.3389\/fimmu.2020.00154","journal-title":"Front Immunol"},{"key":"4670_CR256","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms17122052","volume":"17","author":"Z Wu","year":"2016","unstructured":"Wu Z, Ding N, Yu M et al (2016) Identification of potential biomarkers for rhegmatogenous retinal detachment associated with choroidal detachment by vitreous iTRAQ-based proteomic profiling. Int J Mol Sci 17:1\u201317. https:\/\/doi.org\/10.3390\/ijms17122052","journal-title":"Int J Mol Sci"},{"key":"4670_CR257","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1126\/scitranslmed.aab1482","volume":"7","author":"JH Sweigard","year":"2015","unstructured":"Sweigard JH, Matsumoto H, Smith KE et al (2015) Inhibition of the alternative complement pathway preserves photoreceptors after retinal injury. Sci Transl Med 7:21\u201324. https:\/\/doi.org\/10.1126\/scitranslmed.aab1482","journal-title":"Sci Transl Med"},{"key":"4670_CR258","doi-asserted-by":"publisher","first-page":"4659","DOI":"10.1167\/iovs.14-14818","volume":"55","author":"J Bastiaans","year":"2014","unstructured":"Bastiaans J, van Meurs JC, Mulder VC et al (2014) The role of thrombin in proliferative vitreoretinopathy. Investig Ophthalmol Vis Sci 55:4659\u20134666. https:\/\/doi.org\/10.1167\/iovs.14-14818","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"4670_CR259","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1007\/s00417-013-2335-2","volume":"251","author":"J Bastiaans","year":"2013","unstructured":"Bastiaans J, Van Meurs JC, Van Holten-Neelen C et al (2013) Factor Xa and thrombin stimulate proinflammatory and pro-fibrotic mediator production by retinal pigment epithelial cells: a role in vitreoretinal disorders? Graefe\u2019s Arch Clin Exp Ophthalmol 251:1723\u20131733. https:\/\/doi.org\/10.1007\/s00417-013-2335-2","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"4670_CR260","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1080\/09114300.2018.1451609","volume":"41","author":"K Sato","year":"2018","unstructured":"Sato K, Takeda A, Hasegawa E et al (2018) Interleukin-6 plays a crucial role in the development of subretinal fibrosis in a mouse model. Immunol Med 41:23\u201329. https:\/\/doi.org\/10.1080\/09114300.2018.1451609","journal-title":"Immunol Med"},{"key":"4670_CR261","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.immuni.2013.10.022","volume":"40","author":"CA Fielding","year":"2014","unstructured":"Fielding CA, Jones GW, McLoughlin RM et al (2014) Interleukin-6 signaling drives fibrosis in unresolved inflammation. Immunity 40:40\u201350. https:\/\/doi.org\/10.1016\/j.immuni.2013.10.022","journal-title":"Immunity"},{"key":"4670_CR262","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1016\/j.ajpath.2011.08.043","volume":"179","author":"S Pennock","year":"2011","unstructured":"Pennock S, Rheaume MA, Mukai S, Kazlauskas A (2011) A novel strategy to develop therapeutic approaches to prevent proliferative vitreoretinopathy. Am J Pathol 179:2931\u20132940. https:\/\/doi.org\/10.1016\/j.ajpath.2011.08.043","journal-title":"Am J Pathol"},{"key":"4670_CR263","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/493043","volume":"2012","author":"AM Abu El-Asrar","year":"2012","unstructured":"Abu El-Asrar AM, Imtiaz Nawaz M, Kangave D et al (2012) Osteopontin and other regulators of angiogenesis and fibrogenesis in the vitreous from patients with proliferative vitreoretinal disorders. Mediators Inflamm 2012:1\u20138. https:\/\/doi.org\/10.1155\/2012\/493043","journal-title":"Mediators Inflamm"},{"key":"4670_CR264","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12079-012-0178-y","volume":"7","author":"RJ Van Geest","year":"2013","unstructured":"Van Geest RJ, Klaassen I, Lesnik-Oberstein SY et al (2013) Vitreous TIMP-1 levels associate with neovascularization and TGF-\u03b22 levels but not with fibrosis in the clinical course of proliferative diabetic retinopathy. J Cell Commun Signal 7:1\u20139. https:\/\/doi.org\/10.1007\/s12079-012-0178-y","journal-title":"J Cell Commun Signal"},{"key":"4670_CR265","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1167\/iovs.06-1095","volume":"48","author":"S Mukherjee","year":"2007","unstructured":"Mukherjee S, Guidry C (2007) The insulin-like growth factor system modulates retinal pigment epithelial cell tractional force generation. Investig Ophthalmol Vis Sci 48:1892\u20131899. https:\/\/doi.org\/10.1167\/iovs.06-1095","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"4670_CR266","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3980\/j.issn.2222-3959.2012.03.11","volume":"5","author":"H Zhang","year":"2012","unstructured":"Zhang H, Liu ZL (2012) Transforming growth factor-\u03b2 neutralizing antibodies inhibit subretinal fibrosis in a mouse model. Int J Ophthalmol 5:307\u2013311. https:\/\/doi.org\/10.3980\/j.issn.2222-3959.2012.03.11","journal-title":"Int J Ophthalmol"},{"key":"4670_CR267","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1535370216675245","volume":"242","author":"CG Miller","year":"2017","unstructured":"Miller CG, Budoff G, Prenner JL, Schwarzbauer JE (2017) Minireview: fibronectin in retinal disease. Exp Biol Med 242:1\u20137. https:\/\/doi.org\/10.1177\/1535370216675245","journal-title":"Exp Biol Med"},{"key":"4670_CR268","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.preteyeres.2017.08.001","volume":"60","author":"DY Shu","year":"2017","unstructured":"Shu DY, Lovicu FJ (2017) Myofibroblast transdifferentiation: the dark force in ocular wound healing and fibrosis. Prog Retin Eye Res 60:44\u201365. https:\/\/doi.org\/10.1016\/j.preteyeres.2017.08.001","journal-title":"Prog Retin Eye Res"},{"key":"4670_CR269","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s00109-015-1289-8","volume":"93","author":"K Kimura","year":"2015","unstructured":"Kimura K, Orita T, Liu Y et al (2015) Attenuation of EMT in RPE cells and subretinal fibrosis by an RAR-\u03b3 agonist. J Mol Med 93:749\u2013758. https:\/\/doi.org\/10.1007\/s00109-015-1289-8","journal-title":"J Mol Med"},{"key":"4670_CR270","doi-asserted-by":"publisher","first-page":"17504","DOI":"10.1073\/pnas.0804054105","volume":"105","author":"T Kita","year":"2008","unstructured":"Kita T, Hata Y, Arita R et al (2008) Role of TGF-\u03b2 in proliferative vitreoretinal diseases and ROCK as a therapeutic target. Proc Natl Acad Sci USA 105:17504\u201317509. https:\/\/doi.org\/10.1073\/pnas.0804054105","journal-title":"Proc Natl Acad Sci USA"},{"key":"4670_CR271","first-page":"1010","volume":"18","author":"K Choi","year":"2012","unstructured":"Choi K, Lee K, Ryu SW et al (2012) Pirfenidone inhibits transforming growth factor-\u03b21-induced fibrogenesis by blocking nuclear translocation of smads in human retinal pigment epithelial cell line ARPE-19. Mol Vis 18:1010\u20131020","journal-title":"Mol Vis"},{"key":"4670_CR272","doi-asserted-by":"publisher","first-page":"3212","DOI":"10.1096\/fj.201800858RR","volume":"33","author":"H Yao","year":"2019","unstructured":"Yao H, Ge T, Zhang Y et al (2019) BMP7 antagonizes proliferative vitreoretinopathy through retinal pigment epithelial fibrosis in vivo and in vitro. FASEB J 33:3212\u20133224. https:\/\/doi.org\/10.1096\/fj.201800858RR","journal-title":"FASEB J"},{"key":"4670_CR273","doi-asserted-by":"publisher","first-page":"7956","DOI":"10.7150\/thno.45192","volume":"10","author":"J Fan","year":"2020","unstructured":"Fan J, Shen W, Lee SR et al (2020) Targeting the Notch and TGF-\u03b2 signaling pathways to prevent retinal fibrosis in vitro and in vivo. Theranostics 10:7956\u20137973. https:\/\/doi.org\/10.7150\/thno.45192","journal-title":"Theranostics"},{"key":"4670_CR274","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.exer.2006.10.017","volume":"84","author":"Y Itoh","year":"2007","unstructured":"Itoh Y, Kimoto K, Imaizumi M, Nakatsuka K (2007) Inhibition of RhoA\/Rho-kinase pathway suppresses the expression of type I collagen induced by TGF-\u03b22 in human retinal pigment epithelial cells. Exp Eye Res 84:464\u2013472. https:\/\/doi.org\/10.1016\/j.exer.2006.10.017","journal-title":"Exp Eye Res"},{"key":"4670_CR275","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0122229","volume":"10","author":"Z Dvashi","year":"2015","unstructured":"Dvashi Z, Goldberg M, Adir O et al (2015) TGF-\u03b21 induced transdifferentiation of RPE cells is mediated by TAK1. PLoS ONE 10:1\u201316. https:\/\/doi.org\/10.1371\/journal.pone.0122229","journal-title":"PLoS ONE"},{"key":"4670_CR276","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1038\/eye.2017.21","volume":"31","author":"BNMK Khanum","year":"2017","unstructured":"Khanum BNMK, Guha R, Sur VP et al (2017) Pirfenidone inhibits post-traumatic proliferative vitreoretinopathy. Eye 31:1317\u20131328. https:\/\/doi.org\/10.1038\/eye.2017.21","journal-title":"Eye"},{"key":"4670_CR277","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/1606854","author":"Z Dvashi","year":"2017","unstructured":"Dvashi Z, Ben-Yaakov K, Weinberg T et al (2017) OM-101 decreases the fibrotic response associated with proliferative vitreoretinopathy. J Ophthalmol. https:\/\/doi.org\/10.1155\/2017\/1606854","journal-title":"J Ophthalmol"},{"key":"4670_CR278","first-page":"3649","volume":"35","author":"SG Robbins","year":"1994","unstructured":"Robbins SG, Mixon RN, Wilson DJ et al (1994) Platelet-derived growth factor ligands and receptors immunolocalized in proliferative retinal diseases. Investig Ophthalmol Vis Sci 35:3649\u20133663","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"4670_CR279","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/bjo.82.2.181","volume":"82","author":"L Cassidy","year":"1998","unstructured":"Cassidy L, Barry P, Shaw C et al (1998) Platelet derived growth factor and fibroblast growth factor basic levels in the vitreous of patients with vitreoretinal disorders. Br J Ophthalmol 82:181\u2013185. https:\/\/doi.org\/10.1136\/bjo.82.2.181","journal-title":"Br J Ophthalmol"},{"key":"4670_CR280","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1242\/jcs.107.9.2459","volume":"107","author":"PA Campochiaro","year":"1994","unstructured":"Campochiaro PA, Hackett SF, Vinores SA et al (1994) Platelet-derived growth factor is an autocrine growth stimulator in retinal pigmented epithelial cells. J Cell Sci 107:2459\u20132469","journal-title":"J Cell Sci"},{"key":"4670_CR281","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.exer.2008.10.020","volume":"88","author":"J Cui","year":"2009","unstructured":"Cui J, Lei H, Samad A et al (2009) PDGF receptors are activated in human epiretinal membranes. Exp Eye Res 88:438\u2013444. https:\/\/doi.org\/10.1016\/j.exer.2008.10.020","journal-title":"Exp Eye Res"},{"key":"4670_CR282","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1001\/archopht.1997.01100150239014","volume":"115","author":"PA Campochiaro","year":"1997","unstructured":"Campochiaro PA (1997) Pathogenic mechanisms in proliferative vitreoretinopathy. Arch Ophthalmol 115:237. https:\/\/doi.org\/10.1001\/archopht.1997.01100150239014","journal-title":"Arch Ophthalmol"},{"key":"4670_CR283","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/jcp.20583","volume":"207","author":"H Akiyama","year":"2006","unstructured":"Akiyama H, Kachi S, E Silva RL et al (2006) Intraocular injection of an aptamer that binds PDGF-B: a potential treatment for proliferative retinopathies. J Cell Physiol 207:407\u2013412. https:\/\/doi.org\/10.1002\/jcp.20583","journal-title":"J Cell Physiol"},{"key":"4670_CR284","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/jgm.2629","volume":"14","author":"X Zheng","year":"2012","unstructured":"Zheng X, Du L, Wang H, Gu Q (2012) A novel approach to attenuate proliferative vitreoretinopathy using ultrasound-targeted microbubble destruction and recombinant adeno-associated virus-mediated RNA interference targeting transforming growth factor-\u03b22 and platelet-derived growth factor-B. J Gene Med 14:339\u2013347. https:\/\/doi.org\/10.1002\/jgm.2629","journal-title":"J Gene Med"},{"key":"4670_CR285","doi-asserted-by":"publisher","first-page":"3394","DOI":"10.1167\/iovs.08-3042","volume":"50","author":"H Lei","year":"2009","unstructured":"Lei H, Velez G, Hovland P et al (2009) Growth factors outside the PDGF family drive experimental PVR. Investig Ophthalmol Vis Sci 50:3394\u20133403. https:\/\/doi.org\/10.1167\/iovs.08-3042","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"4670_CR286","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1016\/j.ajpath.2013.01.052","volume":"182","author":"S Pennock","year":"2013","unstructured":"Pennock S, Kim D, Mukai S et al (2013) Ranibizumab is a potential prophylaxis for proliferative vitreoretinopathy, a nonangiogenic blinding disease. Am J Pathol 182:1659\u20131670. https:\/\/doi.org\/10.1016\/j.ajpath.2013.01.052","journal-title":"Am J Pathol"},{"key":"4670_CR287","doi-asserted-by":"publisher","first-page":"6329","DOI":"10.1074\/jbc.M808426200","volume":"284","author":"H Lei","year":"2009","unstructured":"Lei H, Kazlauskas A (2009) Growth factors outside of the platelet-derived growth factor (PDGF) family employ reactive oxygen species\/Src family kinases to activate PDGF receptor \u03b1 and thereby promote proliferation and survival of cells. J Biol Chem 284:6329\u20136336. https:\/\/doi.org\/10.1074\/jbc.M808426200","journal-title":"J Biol Chem"},{"key":"4670_CR288","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.exer.2009.11.003","volume":"90","author":"H Lei","year":"2010","unstructured":"Lei H, Rheaume M-AA, Kazlauskas A (2010) Recent developments in our understanding of how platelet-derived growth factor (PDGF) and its receptors contribute to proliferative vitreoretinopathy. Exp Eye Res 90:376\u2013381. https:\/\/doi.org\/10.1016\/j.exer.2009.11.003","journal-title":"Exp Eye Res"},{"key":"4670_CR289","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1016\/j.ajpath.2014.07.026","volume":"184","author":"S Pennock","year":"2014","unstructured":"Pennock S, Haddock LJ, Mukai S, Kazlauskas A (2014) Vascular endothelial growth factor acts primarily via platelet-derived growth factor receptor \u03b1 to promote proliferative vitreoretinopathy. Am J Pathol 184:3052\u20133068. https:\/\/doi.org\/10.1016\/j.ajpath.2014.07.026","journal-title":"Am J Pathol"},{"key":"4670_CR290","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1136\/bjophthalmol-2011-301005","volume":"96","author":"RJ Van Geest","year":"2012","unstructured":"Van Geest RJ, Lesnik-Oberstein SY, Tan HS et al (2012) A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy. Br J Ophthalmol 96:587\u2013590. https:\/\/doi.org\/10.1136\/bjophthalmol-2011-301005","journal-title":"Br J Ophthalmol"},{"key":"4670_CR291","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0002675","volume":"3","author":"EJ Kuiper","year":"2008","unstructured":"Kuiper EJ, Van Nieuwenhoven FA, de Smet MD et al (2008) The angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy. PLoS ONE 3:1\u20137. https:\/\/doi.org\/10.1371\/journal.pone.0002675","journal-title":"PLoS ONE"},{"key":"4670_CR292","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.exer.2014.10.016","volume":"133","author":"I Klaassen","year":"2015","unstructured":"Klaassen I, van Geest RJ, Kuiper EJ et al (2015) The role of CTGF in diabetic retinopathy. Exp Eye Res 133:37\u201348. https:\/\/doi.org\/10.1016\/j.exer.2014.10.016","journal-title":"Exp Eye Res"},{"key":"4670_CR293","doi-asserted-by":"publisher","first-page":"5783","DOI":"10.1167\/iovs.17-22345","volume":"58","author":"Q Wei","year":"2017","unstructured":"Wei Q, Zhang T, Jiang R et al (2017) Vitreous fibronectin and fibrinogen expression increased in eyes with proliferative diabetic retinopathy after intravitreal anti-VEGF therapy. Investig Ophthalmol Vis Sci 58:5783\u20135791. https:\/\/doi.org\/10.1167\/iovs.17-22345","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"4670_CR294","doi-asserted-by":"publisher","first-page":"637","DOI":"10.2147\/CIA.S52662","volume":"9","author":"MD Pinazo-Dur\u00e1n","year":"2014","unstructured":"Pinazo-Dur\u00e1n MD, Gallego-Pinazo R, Garc\u00eda-Medina JJ et al (2014) Oxidative stress and its downstream signaling in aging eyes. Clin Interv Aging 9:637\u2013652. https:\/\/doi.org\/10.2147\/CIA.S52662","journal-title":"Clin Interv Aging"},{"key":"4670_CR295","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/S0167-4943(02)00013-4","volume":"34","author":"A Berra","year":"2002","unstructured":"Berra A, Ferreira S, Stanga P, Llesuy S (2002) Age-related antioxidant capacity of the vitreous and its possible relationship with simultaneous changes in photoreceptors, retinal pigment epithelium and Bruchs\u2019 membrane in human donors\u2019 eyes. Arch Gerontol Geriatr 34:371\u2013377. https:\/\/doi.org\/10.1016\/S0167-4943(02)00013-4","journal-title":"Arch Gerontol Geriatr"},{"key":"4670_CR296","doi-asserted-by":"publisher","first-page":"505","DOI":"10.3390\/antiox11030505","volume":"11","author":"FM Santos","year":"2022","unstructured":"Santos FM, Mesquita J, Castro-de-Sousa JP et al (2022) Vitreous humor proteome: targeting oxidative stress, inflammation, and neurodegeneration in vitreoretinal diseases. Antioxidants 11:505. https:\/\/doi.org\/10.3390\/antiox11030505","journal-title":"Antioxidants"},{"key":"4670_CR297","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/3164734","volume":"2016","author":"M Nita","year":"2016","unstructured":"Nita M, Grzybowski A (2016) The role of the reactive oxygen species and oxidative stress in the pathomechanism of the age-related ocular diseases and other pathologies of the anterior and posterior eye segments in adults. Oxid Med Cell Longev 2016:1\u201323. https:\/\/doi.org\/10.1155\/2016\/3164734","journal-title":"Oxid Med Cell Longev"},{"key":"4670_CR298","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/antiox9010007","volume":"9","author":"E Ankamah","year":"2019","unstructured":"Ankamah E, Sebag J, Ng E, Nolan JM (2019) Vitreous antioxidants, degeneration, and vitreo-retinopathy: exploring the links. Antioxidants 9:1\u201320. https:\/\/doi.org\/10.3390\/antiox9010007","journal-title":"Antioxidants"},{"key":"4670_CR299","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.mam.2012.03.009","volume":"33","author":"SG Jarrett","year":"2012","unstructured":"Jarrett SG, Boulton ME (2012) Consequences of oxidative stress in age-related macular degeneration. Mol Aspects Med 33:399\u2013417. https:\/\/doi.org\/10.1016\/j.mam.2012.03.009","journal-title":"Mol Aspects Med"},{"key":"4670_CR300","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.preteyeres.2015.05.001","volume":"48","author":"RA Kowluru","year":"2015","unstructured":"Kowluru RA, Kowluru A, Mishra M, Kumar B (2015) Oxidative stress and epigenetic modifications in the pathogenesis of diabetic retinopathy. Prog Retin Eye Res 48:40\u201361. https:\/\/doi.org\/10.1016\/j.preteyeres.2015.05.001","journal-title":"Prog Retin Eye Res"},{"key":"4670_CR301","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s11154-008-9090-4","volume":"9","author":"SA Madsen-Bouterse","year":"2008","unstructured":"Madsen-Bouterse SA, Kowluru RA (2008) Oxidative stress and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Rev Endocr Metab Disord 9:315\u2013327. https:\/\/doi.org\/10.1007\/s11154-008-9090-4","journal-title":"Rev Endocr Metab Disord"},{"key":"4670_CR302","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/4940825","volume":"2019","author":"ML Rodr\u00edguez","year":"2019","unstructured":"Rodr\u00edguez ML, P\u00e9rez S, Mena-Moll\u00e1 S et al (2019) Oxidative stress and microvascular alterations in diabetic retinopathy: future therapies. Oxid Med Cell Longev 2019:1\u201318. https:\/\/doi.org\/10.1155\/2019\/4940825","journal-title":"Oxid Med Cell Longev"},{"key":"4670_CR303","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.redox.2020.101799","volume":"37","author":"Q Kang","year":"2020","unstructured":"Kang Q, Yang C (2020) Oxidative stress and diabetic retinopathy: molecular mechanisms, pathogenetic role and therapeutic implications. Redox Biol 37:1\u201317. https:\/\/doi.org\/10.1016\/j.redox.2020.101799","journal-title":"Redox Biol"},{"key":"4670_CR304","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.preteyeres.2017.03.002","volume":"60","author":"S Datta","year":"2017","unstructured":"Datta S, Cano M, Ebrahimi K et al (2017) The impact of oxidative stress and inflammation on RPE degeneration in non-neovascular AMD. Prog Retin Eye Res 60:201\u2013218. https:\/\/doi.org\/10.1016\/j.preteyeres.2017.03.002","journal-title":"Prog Retin Eye Res"},{"key":"4670_CR305","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/7532507","author":"A Maugeri","year":"2018","unstructured":"Maugeri A, Barchitta M, Mazzone MG et al (2018) Complement system and age-related macular degeneration: implications of gene-environment interaction for preventive and personalized medicine. Biomed Res Int. https:\/\/doi.org\/10.1155\/2018\/7532507","journal-title":"Biomed Res Int"},{"key":"4670_CR306","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.exer.2009.12.011","volume":"90","author":"TU Krohne","year":"2010","unstructured":"Krohne TU, Stratmann NK, Kopitz J, Holz FG (2010) Effects of lipid peroxidation products on lipofuscinogenesis and autophagy in human retinal pigment epithelial cells. Exp Eye Res 90:465\u2013471. https:\/\/doi.org\/10.1016\/j.exer.2009.12.011","journal-title":"Exp Eye Res"},{"key":"4670_CR307","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.exer.2015.08.018","volume":"144","author":"D Sinha","year":"2016","unstructured":"Sinha D, Valapala M, Shang P et al (2016) Lysosomes: regulators of autophagy in the retinal pigmented epithelium. Exp Eye Res 144:46\u201353. https:\/\/doi.org\/10.1016\/j.exer.2015.08.018","journal-title":"Exp Eye Res"},{"key":"4670_CR308","doi-asserted-by":"crossref","unstructured":"Kwon YH, Kim YA, Yoo YH (2017) Loss of pigment epithelial cells is prevented by autophagy. In: Autophagy: cancer, other pathologies, inflammation, immunity, infection, and aging, 11th edn. Elsevier, pp 105\u2013117","DOI":"10.1016\/B978-0-12-805420-8.00003-2"},{"key":"4670_CR309","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0004160","volume":"4","author":"AL Wang","year":"2009","unstructured":"Wang AL, Lukas TJ, Yuan M et al (2009) Autophagy and exosomes in the aged retinal pigment epithelium: possible relevance to drusen formation and age-related macular degeneration. PLoS ONE 4:1\u201313. https:\/\/doi.org\/10.1371\/journal.pone.0004160","journal-title":"PLoS ONE"},{"key":"4670_CR310","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.arr.2017.03.006","volume":"36","author":"JMT Hyttinen","year":"2017","unstructured":"Hyttinen JMT, B\u0142asiak J, Niittykoski M et al (2017) DNA damage response and autophagy in the degeneration of retinal pigment epithelial cells\u2014implications for age-related macular degeneration (AMD). Ageing Res Rev 36:64\u201377. https:\/\/doi.org\/10.1016\/j.arr.2017.03.006","journal-title":"Ageing Res Rev"},{"key":"4670_CR311","doi-asserted-by":"publisher","first-page":"13067","DOI":"10.1073\/pnas.202491599","volume":"99","author":"LY Marmorstein","year":"2002","unstructured":"Marmorstein LY, Munier FL, Arsenijevic Y et al (2002) Aberrant accumulation of EFEMP1 underlies drusen formation in Malattia Leventinese and age-related macular degeneration. Proc Natl Acad Sci 99:13067\u201313072. https:\/\/doi.org\/10.1073\/pnas.202491599","journal-title":"Proc Natl Acad Sci"},{"key":"4670_CR312","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1089\/ars.2011.3906","volume":"15","author":"T Frey","year":"2011","unstructured":"Frey T, Antonetti DA (2011) Alterations to the blood-retinal barrier in diabetes: cytokines and reactive oxygen species. Antioxidants Redox Signal 15:1271\u20131284. https:\/\/doi.org\/10.1089\/ars.2011.3906","journal-title":"Antioxidants Redox Signal"},{"key":"4670_CR313","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S0039-6257(00)00140-5","volume":"45","author":"S Beatty","year":"2000","unstructured":"Beatty S, Koh HH, Phil M et al (2000) The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 45:115\u2013134. https:\/\/doi.org\/10.1016\/S0039-6257(00)00140-5","journal-title":"Surv Ophthalmol"},{"key":"4670_CR314","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/3940241","volume":"2017","author":"JC Rivera","year":"2017","unstructured":"Rivera JC, Dabouz R, Noueihed B et al (2017) Ischemic retinopathies: oxidative stress and inflammation. Oxid Med Cell Longev 2017:1\u201316. https:\/\/doi.org\/10.1155\/2017\/3940241","journal-title":"Oxid Med Cell Longev"},{"key":"4670_CR315","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/cbf.3292","volume":"35","author":"JA Ko","year":"2017","unstructured":"Ko JA, Sotani Y, Ibrahim DG, Kiuchi Y (2017) Role of macrophage migration inhibitory factor (MIF) in the effects of oxidative stress on human retinal pigment epithelial cells. Cell Biochem Funct 35:426\u2013432. https:\/\/doi.org\/10.1002\/cbf.3292","journal-title":"Cell Biochem Funct"},{"key":"4670_CR316","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-60785-x","volume":"10","author":"I-H Yang","year":"2020","unstructured":"Yang I-H, Lee J-J, Wu P-C et al (2020) Oxidative stress enhanced the transforming growth factor-\u03b22-induced epithelial-mesenchymal transition through chemokine ligand 1 on ARPE-19 cell. Sci Rep 10:1\u201310. https:\/\/doi.org\/10.1038\/s41598-020-60785-x","journal-title":"Sci Rep"},{"key":"4670_CR317","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.mehy.2016.10.027","volume":"97","author":"Y Tong","year":"2016","unstructured":"Tong Y, Zhou YL, Wang YX et al (2016) Retinal pigment epithelium cell-derived exosomes: possible relevance to CNV in wet-age related macular degeneration. Med Hypotheses 97:98\u2013101. https:\/\/doi.org\/10.1016\/j.mehy.2016.10.027","journal-title":"Med Hypotheses"},{"key":"4670_CR318","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1111\/jcmm.12834","volume":"20","author":"S Atienzar-Aroca","year":"2016","unstructured":"Atienzar-Aroca S, Flores-Bellver M, Serrano-Heras G et al (2016) Oxidative stress in retinal pigment epithelium cells increases exosome secretion and promotes angiogenesis in endothelial cells. J Cell Mol Med 20:1457\u20131466. https:\/\/doi.org\/10.1111\/jcmm.12834","journal-title":"J Cell Mol Med"},{"key":"4670_CR319","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1021\/pr400751k","volume":"13","author":"G-Y Kang","year":"2014","unstructured":"Kang G-Y, Bang JY, Choi AJ et al (2014) Exosomal proteins in the aqueous humor as novel biomarkers in patients with neovascular age-related macular degeneration. J Proteome Res 13:581\u2013595. https:\/\/doi.org\/10.1021\/pr400751k","journal-title":"J Proteome Res"},{"key":"4670_CR320","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/j.febslet.2013.05.020","volume":"587","author":"D Athanasiou","year":"2013","unstructured":"Athanasiou D, Aguil\u00e0 M, Bevilacqua D et al (2013) The cell stress machinery and retinal degeneration. FEBS Lett 587:2008\u20132017. https:\/\/doi.org\/10.1016\/j.febslet.2013.05.020","journal-title":"FEBS Lett"},{"key":"4670_CR321","doi-asserted-by":"publisher","first-page":"164","DOI":"10.2174\/157015908784533851","volume":"6","author":"K-G Schmidt","year":"2008","unstructured":"Schmidt K-G, Bergert H, Funk R (2008) Neurodegenerative diseases of the retina and potential for protection and recovery. Curr Neuropharmacol 6:164\u2013178. https:\/\/doi.org\/10.2174\/157015908784533851","journal-title":"Curr Neuropharmacol"},{"key":"4670_CR322","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1159\/000434703","volume":"55","author":"YM Paulus","year":"2015","unstructured":"Paulus YM, Campbell JP (2015) Neuroprotection and retinal diseases. Dev Ophthalmol 55:322\u2013329. https:\/\/doi.org\/10.1159\/000434703","journal-title":"Dev Ophthalmol"},{"key":"4670_CR323","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1007\/s00125-018-4692-1","volume":"61","author":"R Sim\u00f3","year":"2018","unstructured":"Sim\u00f3 R, Stitt AW, Gardner TW (2018) Neurodegeneration in diabetic retinopathy: does it really matter? Diabetologia 61:1902\u20131912. https:\/\/doi.org\/10.1007\/s00125-018-4692-1","journal-title":"Diabetologia"},{"key":"4670_CR324","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.visres.2017.06.014","volume":"139","author":"AJ Barber","year":"2017","unstructured":"Barber AJ, Baccouche B (2017) Neurodegeneration in diabetic retinopathy: potential for novel therapies. Vision Res 139:82\u201392. https:\/\/doi.org\/10.1016\/j.visres.2017.06.014","journal-title":"Vision Res"},{"key":"4670_CR325","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-019-1134-5","author":"S Zafar","year":"2019","unstructured":"Zafar S, Sachdeva M, Frankfort BJ, Channa R (2019) Retinal neurodegeneration as an early manifestation of diabetic eye disease and potential neuroprotective therapies. Curr Diab Rep. https:\/\/doi.org\/10.1007\/s11892-019-1134-5","journal-title":"Curr Diab Rep"},{"key":"4670_CR326","doi-asserted-by":"crossref","unstructured":"Nian S, C.Y. Lo A (2019) Protecting the aging retina. In: Neuroprotection. IntechOpen, p 13","DOI":"10.5772\/intechopen.82330"},{"key":"4670_CR327","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/j.ddstr.2012.07.001","volume":"10","author":"ND Chinskey","year":"2013","unstructured":"Chinskey ND, Besirli CG, Zacks DN (2013) Retinal neuroprotection in dry age-related macular degeneration. Drug Discov Today Ther Strateg 10:e21\u2013e24. https:\/\/doi.org\/10.1016\/j.ddstr.2012.07.001","journal-title":"Drug Discov Today Ther Strateg"},{"key":"4670_CR328","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1159\/000328206","volume":"226","author":"ACY Lo","year":"2011","unstructured":"Lo ACY, Woo TTY, Wong RLM, Wong D (2011) Apoptosis and other cell death mechanisms after retinal detachment: Implications for photoreceptor rescue. Ophthalmologica 226:10\u201317. https:\/\/doi.org\/10.1159\/000328206","journal-title":"Ophthalmologica"},{"key":"4670_CR329","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.preteyeres.2013.08.001","volume":"37","author":"Y Murakami","year":"2013","unstructured":"Murakami Y, Notomi S, Hisatomi T et al (2013) Photoreceptor cell death and rescue in retinal detachment and degenerations. Prog Retin Eye Res 37:114\u2013140. https:\/\/doi.org\/10.1016\/j.preteyeres.2013.08.001","journal-title":"Prog Retin Eye Res"},{"key":"4670_CR330","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.preteyeres.2014.07.001","volume":"43","author":"N Cuenca","year":"2014","unstructured":"Cuenca N, Fern\u00e1ndez-S\u00e1nchez L, Campello L et al (2014) Cellular responses following retinal injuries and therapeutic approaches for neurodegenerative diseases. Prog Retin Eye Res 43:17\u201375. https:\/\/doi.org\/10.1016\/j.preteyeres.2014.07.001","journal-title":"Prog Retin Eye Res"},{"key":"4670_CR331","doi-asserted-by":"crossref","unstructured":"Fortuny C, Flannery JG (2018) Mutation-independent gene therapies for rod-cone dystrophies. pp 75\u201381","DOI":"10.1007\/978-3-319-75402-4_10"},{"key":"4670_CR332","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/673090","author":"MH Madeira","year":"2015","unstructured":"Madeira MH, Boia R, Santos PF et al (2015) Contribution of microglia-mediated neuroinflammation to retinal degenerative diseases. Mediators Inflamm. https:\/\/doi.org\/10.1155\/2015\/673090","journal-title":"Mediators Inflamm"},{"key":"4670_CR333","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.cyto.2017.02.013","volume":"95","author":"M Ponnalagu","year":"2017","unstructured":"Ponnalagu M, Subramani M, Jayadev C et al (2017) Retinal pigment epithelium-secretome: a diabetic retinopathy perspective. Cytokine 95:126\u2013135. https:\/\/doi.org\/10.1016\/j.cyto.2017.02.013","journal-title":"Cytokine"},{"key":"4670_CR334","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.survophthal.2005.06.004","volume":"50","author":"OV Kubay","year":"2005","unstructured":"Kubay OV, Charteris DG, Newland HS, Raymond GL (2005) Retinal detachment neuropathology and potential strategies for neuroprotection. Surv Ophthalmol 50:463\u2013475. https:\/\/doi.org\/10.1016\/j.survophthal.2005.06.004","journal-title":"Surv Ophthalmol"},{"key":"4670_CR335","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19010110","author":"C Altmann","year":"2018","unstructured":"Altmann C, Schmidt MHH (2018) The role of microglia in diabetic retinopathy: inflammation, microvasculature defects and neurodegeneration. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms19010110","journal-title":"Int J Mol Sci"},{"key":"4670_CR336","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0093343","author":"M Rutar","year":"2014","unstructured":"Rutar M, Valter K, Natoli R, Provis JM (2014) Synthesis and propagation of complement C3 by microglia\/monocytes in the aging retina. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0093343","journal-title":"PLoS ONE"},{"key":"4670_CR337","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.brainresrev.2011.01.002","volume":"67","author":"A Spooren","year":"2011","unstructured":"Spooren A, Kolmus K, Laureys G et al (2011) Interleukin-6, a mental cytokine. Brain Res Rev 67:157\u2013183. https:\/\/doi.org\/10.1016\/j.brainresrev.2011.01.002","journal-title":"Brain Res Rev"},{"key":"4670_CR338","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.7150\/ijbs.4679","volume":"8","author":"M Erta","year":"2012","unstructured":"Erta M, Quintana A, Hidalgo J (2012) Interleukin-6, a major cytokine in the central nervous system. Int J Biol Sci 8:1254\u20131266. https:\/\/doi.org\/10.7150\/ijbs.4679","journal-title":"Int J Biol Sci"},{"key":"4670_CR339","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms19113363","volume":"19","author":"GM Tosi","year":"2018","unstructured":"Tosi GM, Orlandini M, Galvagni F (2018) The controversial role of TGF-\u03b2 in neovascular age-related macular degeneration pathogenesis. Int J Mol Sci 19:1\u201316. https:\/\/doi.org\/10.3390\/ijms19113363","journal-title":"Int J Mol Sci"},{"key":"4670_CR340","doi-asserted-by":"publisher","first-page":"8219","DOI":"10.3390\/ijms13078219","volume":"13","author":"A Dobolyi","year":"2012","unstructured":"Dobolyi A, Vincze C, P\u00e1l G, Lovas G (2012) The neuroprotective functions of transforming growth factor beta proteins. Int J Mol Sci 13:8219\u20138258. https:\/\/doi.org\/10.3390\/ijms13078219","journal-title":"Int J Mol Sci"},{"key":"4670_CR341","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.4103\/1673-5374.235024","volume":"13","author":"P Calvo","year":"2018","unstructured":"Calvo P, Pastor A, De La Cruz R (2018) Vascular endothelial growth factor: an essential neurotrophic factor for motoneurons? Neural Regen Res 13:1181\u20131182. https:\/\/doi.org\/10.4103\/1673-5374.235024","journal-title":"Neural Regen Res"},{"key":"4670_CR342","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1007\/s00417-015-3127-7","volume":"253","author":"AGM J\u00fcnemann","year":"2015","unstructured":"J\u00fcnemann AGM, Rejdak R, Huchzermeyer C et al (2015) Elevated vitreous body glial fibrillary acidic protein in retinal diseases. Graefe\u2019s Arch Clin Exp Ophthalmol 253:2181\u20132186. https:\/\/doi.org\/10.1007\/s00417-015-3127-7","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"4670_CR343","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1167\/IOVS.61.5.22","volume":"61","author":"SY Lee","year":"2020","unstructured":"Lee SY, Surbeck JW, Drake M et al (2020) Increased glial fibrillary acid protein and vimentin in vitreous fluid as a biomarker for proliferative vitreoretinopathy. Investig Ophthalmol Vis Sci 61:1\u20138. https:\/\/doi.org\/10.1167\/IOVS.61.5.22","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"4670_CR344","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.exer.2018.08.016","volume":"177","author":"K Eastlake","year":"2018","unstructured":"Eastlake K, Heywood WE, Banerjee P et al (2018) Comparative proteomic analysis of normal and gliotic PVR retina and contribution of M\u00fcller glia to this profile. Exp Eye Res 177:197\u2013207. https:\/\/doi.org\/10.1016\/j.exer.2018.08.016","journal-title":"Exp Eye Res"},{"key":"4670_CR345","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.1167\/iovs.06-1398","volume":"48","author":"T Nakazawa","year":"2007","unstructured":"Nakazawa T, Takeda M, Lewis GP et al (2007) Attenuated glial reactions and photoreceptor degeneration after retinal detachment in mice deficient in glial fibrillary acidic protein and vimentin. Investig Ophthalmol Vis Sci 48:2760\u20132768. https:\/\/doi.org\/10.1167\/iovs.06-1398","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"4670_CR346","doi-asserted-by":"publisher","first-page":"3659","DOI":"10.1167\/iovs.07-1474","volume":"49","author":"MR Verardo","year":"2008","unstructured":"Verardo MR, Lewis GP, Takeda M et al (2008) Abnormal reactivity of M\u00fcller cells after retinal detachment in mice deficient in GFAP and vimentin. Investig Ophthalmol Vis Sci 49:3659\u20133665. https:\/\/doi.org\/10.1167\/iovs.07-1474","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"4670_CR347","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci8020033","author":"A Haque","year":"2018","unstructured":"Haque A, Polcyn R, Matzelle D, Banik NL (2018) New insights into the role of neuron-specific enolase in neuroinflammation, neurodegeneration, and neuroprotection. Brain Sci. https:\/\/doi.org\/10.3390\/brainsci8020033","journal-title":"Brain Sci"},{"key":"4670_CR348","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s00281-015-0518-0","volume":"37","author":"M Gold","year":"2015","unstructured":"Gold M, El Khoury J (2015) \u03b2-amyloid, microglia, and the inflammasome in Alzheimer\u2019s disease. Semin Immunopathol 37:607\u2013611. https:\/\/doi.org\/10.1007\/s00281-015-0518-0","journal-title":"Semin Immunopathol"},{"key":"4670_CR349","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1515\/raon-2015-0035","volume":"49","author":"T Vizin","year":"2015","unstructured":"Vizin T, Kos J (2015) Gamma-enolase: a well-known tumour marker, with a less-known role in cancer. Radiol Oncol 49:217\u2013226. https:\/\/doi.org\/10.1515\/raon-2015-0035","journal-title":"Radiol Oncol"},{"key":"4670_CR350","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/eye.2015.100","volume":"29","author":"JA Ratnayaka","year":"2015","unstructured":"Ratnayaka JA, Serpell LC, Lotery AJ (2015) Dementia of the eye: the role of amyloid beta in retinal degeneration. Eye 29:1013\u20131026. https:\/\/doi.org\/10.1038\/eye.2015.100","journal-title":"Eye"},{"key":"4670_CR351","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1172\/JCI25843","volume":"116","author":"V Luibl","year":"2006","unstructured":"Luibl V, Isas JM, Kayed R et al (2006) Drusen deposits associated with aging and age-related macular degeneration contain nonfibrillar amyloid oligomers. J Clin Invest 116:378\u2013385. https:\/\/doi.org\/10.1172\/JCI25843","journal-title":"J Clin Invest"},{"key":"4670_CR352","doi-asserted-by":"publisher","first-page":"4279","DOI":"10.1007\/s00018-016-2295-x","volume":"73","author":"VBV Gupta","year":"2016","unstructured":"Gupta VBV, Gupta VBV, Chitranshi N et al (2016) One protein, multiple pathologies: multifaceted involvement of amyloid \u03b2 in neurodegenerative disorders of the brain and retina. Cell Mol Life Sci 73:4279\u20134297. https:\/\/doi.org\/10.1007\/s00018-016-2295-x","journal-title":"Cell Mol Life Sci"},{"key":"4670_CR353","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.freeradbiomed.2008.10.043","volume":"46","author":"L Zheng","year":"2009","unstructured":"Zheng L, K\u00e5gedal K, Dehvari N et al (2009) Oxidative stress induces macroautophagy of amyloid \u03b2-protein and ensuing apoptosis. Free Radic Biol Med 46:422\u2013429. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2008.10.043","journal-title":"Free Radic Biol Med"},{"key":"4670_CR354","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.preteyeres.2012.06.001","volume":"31","author":"R Kannan","year":"2012","unstructured":"Kannan R, Sreekumar PG, Hinton DR (2012) Novel roles for \u03b1-crystallins in retinal function and disease. Prog Retin Eye Res 31:576\u2013604. https:\/\/doi.org\/10.1016\/j.preteyeres.2012.06.001","journal-title":"Prog Retin Eye Res"},{"key":"4670_CR355","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0098275","volume":"9","author":"P Zhou","year":"2014","unstructured":"Zhou P, Kannan R, Spee C et al (2014) Protection of retina by \u03b1B crystallin in sodium iodate induced retinal degeneration. PLoS ONE 9:1\u201315. https:\/\/doi.org\/10.1371\/journal.pone.0098275","journal-title":"PLoS ONE"},{"key":"4670_CR356","doi-asserted-by":"publisher","first-page":"8265","DOI":"10.1167\/iovs.12-10334","volume":"53","author":"MRR B\u00f6hm","year":"2012","unstructured":"B\u00f6hm MRR, Pfrommer S, Chiwitt C et al (2012) Crystallin-\u03b2-b2-overexpressing NPCs support the survival of injured retinal ganglion cells and photoreceptors in rats. Investig Ophthalmol Vis Sci 53:8265\u20138279. https:\/\/doi.org\/10.1167\/iovs.12-10334","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"4670_CR357","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.ajpath.2010.11.072","volume":"178","author":"M Kayama","year":"2011","unstructured":"Kayama M, Nakazawa T, Thanos A et al (2011) Heat shock protein 70 (HSP70) is critical for the photoreceptor stress response after retinal detachment via modulating anti-apoptotic Akt kinase. Am J Pathol 178:1080\u20131091. https:\/\/doi.org\/10.1016\/j.ajpath.2010.11.072","journal-title":"Am J Pathol"},{"key":"4670_CR358","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/cddis.2016.453","volume":"8","author":"N Golestaneh","year":"2018","unstructured":"Golestaneh N, Chu Y, Xiao Y-Y et al (2018) Dysfunctional autophagy in RPE, a contributing factor in age-related macular degeneration. Cell Death Dis 8:1\u201313. https:\/\/doi.org\/10.1038\/cddis.2016.453","journal-title":"Cell Death Dis"},{"key":"4670_CR359","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-59244-4","volume":"10","author":"M Zhang","year":"2020","unstructured":"Zhang M, Jiang N, Chu Y et al (2020) Dysregulated metabolic pathways in age-related macular degeneration. Sci Rep 10:1\u201314. https:\/\/doi.org\/10.1038\/s41598-020-59244-4","journal-title":"Sci Rep"},{"key":"4670_CR360","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scisignal.aag3315","volume":"11","author":"B Yu","year":"2018","unstructured":"Yu B, Egbejimi A, Dharmat R et al (2018) Phagocytosed photoreceptor outer segments activate mTORC1 in the retinal pigment epithelium. Sci Signal 11:1\u201314. https:\/\/doi.org\/10.1126\/scisignal.aag3315","journal-title":"Sci Signal"},{"key":"4670_CR361","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1172\/JCI44303","volume":"121","author":"C Zhao","year":"2011","unstructured":"Zhao C, Yasumura D, Li X et al (2011) mTOR-mediated dedifferentiation of the retinal pigment epithelium initiates photoreceptor degeneration in mice. J Clin Invest 121:369\u2013383. https:\/\/doi.org\/10.1172\/JCI44303","journal-title":"J Clin Invest"},{"key":"4670_CR362","doi-asserted-by":"crossref","unstructured":"Gale J, Aiello LP, Sebag J (2014) I.E. Diabetic Vitreopathy. In: Vitreous. Springer New York, New York, pp 57\u201379","DOI":"10.1007\/978-1-4939-1086-1_5"},{"key":"4670_CR363","doi-asserted-by":"publisher","first-page":"a005058","DOI":"10.1101\/cshperspect.a005058","volume":"3","author":"P Lu","year":"2011","unstructured":"Lu P, Takai K, Weaver VM, Werb Z (2011) Extracellular matrix degradation and remodeling in development and disease. Cold Spring Harb Perspect Biol 3:a005058\u2013a005058. https:\/\/doi.org\/10.1101\/cshperspect.a005058","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"4670_CR364","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/nrm3904","volume":"15","author":"C Bonnans","year":"2014","unstructured":"Bonnans C, Chou J, Werb Z (2014) Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol 15:786\u2013801. https:\/\/doi.org\/10.1038\/nrm3904","journal-title":"Nat Rev Mol Cell Biol"},{"key":"4670_CR365","first-page":"3299","volume":"41","author":"A Vaughan-Thomas","year":"2000","unstructured":"Vaughan-Thomas A, Gilbert SJ, Duance VC (2000) Elevated levels of proteolytic enzymes in the aging human vitreous. Investig Ophthalmol Vis Sci 41:3299\u20133304","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"4670_CR366","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1517\/13543784.2012.681043","volume":"21","author":"RA Kowluru","year":"2012","unstructured":"Kowluru RA, Zhong Q, Santos JM (2012) Matrix metalloproteinases in diabetic retinopathy: potential role of MMP-9. Expert Opin Investig Drugs 21:797\u2013805. https:\/\/doi.org\/10.1517\/13543784.2012.681043","journal-title":"Expert Opin Investig Drugs"},{"key":"4670_CR367","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1097\/IAE.0b013e3180592c00","volume":"27","author":"C Symeonidis","year":"2007","unstructured":"Symeonidis C, Diza E, Papakonstantinou E et al (2007) Correlation of the extent and duration of rhegmatogenous retinal detachment with the expression of matrix metalloproteinases in the vitreous. Retina 27:1279\u20131285. https:\/\/doi.org\/10.1097\/IAE.0b013e3180592c00","journal-title":"Retina"},{"key":"4670_CR368","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/j.1755-3768.2009.01701.x","volume":"89","author":"C Symeonidis","year":"2011","unstructured":"Symeonidis C, Papakonstantinou E, Souliou E et al (2011) Correlation of matrix metalloproteinase levels with the grade of proliferative vitreoretinopathy in the subretinal fluid and vitreous during rhegmatogenous retinal detachment. Acta Ophthalmol 89:339\u2013345. https:\/\/doi.org\/10.1111\/j.1755-3768.2009.01701.x","journal-title":"Acta Ophthalmol"},{"key":"4670_CR369","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/00006982-200102000-00005","volume":"21","author":"M Jin","year":"2001","unstructured":"Jin M, Kashiwagi K, Iizuka Y et al (2001) Matrix metalloproteinases in human diabetic and nondiabetic vitreous. Retina 21:28\u201333. https:\/\/doi.org\/10.1097\/00006982-200102000-00005","journal-title":"Retina"},{"key":"4670_CR370","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.exer.2014.10.021","volume":"133","author":"PN Bishop","year":"2015","unstructured":"Bishop PN (2015) The role of extracellular matrix in retinal vascular development and preretinal neovascularization. Exp Eye Res 133:30\u201336. https:\/\/doi.org\/10.1016\/j.exer.2014.10.021","journal-title":"Exp Eye Res"},{"key":"4670_CR371","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.18240\/ijo.2017.08.20","volume":"10","author":"M Singh","year":"2017","unstructured":"Singh M, Tyagi SC (2017) Metalloproteinases as mediators of inflammation and the eyes: molecular genetic underpinnings governing ocular pathophysiology. Int J Ophthalmol 10:1308\u20131318. https:\/\/doi.org\/10.18240\/ijo.2017.08.20","journal-title":"Int J Ophthalmol"},{"key":"4670_CR372","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1172\/JCI31487","volume":"117","author":"TA Wynn","year":"2007","unstructured":"Wynn TA (2007) Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest 117:524\u2013529. https:\/\/doi.org\/10.1172\/JCI31487","journal-title":"J Clin Invest"},{"key":"4670_CR373","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1177\/112067210501500312","volume":"15","author":"E Ioachim","year":"2005","unstructured":"Ioachim E, Stefaniotou M, Gorezis S et al (2005) Immunohistochemical study of extracellular matrix components in epiretinal membranes of vitreoproliferative retinopathy and proliferative diabetic retinopathy. Eur J Ophthalmol 15:384\u2013391. https:\/\/doi.org\/10.1177\/112067210501500312","journal-title":"Eur J Ophthalmol"},{"key":"4670_CR374","doi-asserted-by":"publisher","first-page":"4459","DOI":"10.1167\/iovs.10-6678","volume":"52","author":"AA Hussain","year":"2011","unstructured":"Hussain AA, Lee Y, Zhang JJ, Marshall J (2011) Disturbed matrix metalloproteinase activity of Bruch\u2019s membrane in age-related macular degeneration. Investig Ophthalmol Vis Sci 52:4459\u20134466. https:\/\/doi.org\/10.1167\/iovs.10-6678","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"4670_CR375","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1096\/fj.03-0113fje","volume":"17","author":"V Lambert","year":"2003","unstructured":"Lambert V, Wielockx B, Munaut C et al (2003) MMP-2 and MMP-9 synergize in promoting choroidal neovascularization. FASEB J 17:2290\u20132292. https:\/\/doi.org\/10.1096\/fj.03-0113fje","journal-title":"FASEB J"},{"key":"4670_CR376","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S0021-5155(98)00038-0","volume":"42","author":"T Matsuo","year":"1998","unstructured":"Matsuo T (1998) TIMP-1 and TIMP-2 levels in vitreous and subretinal fluid. Jpn J Ophthalmol 42:377\u2013380. https:\/\/doi.org\/10.1016\/S0021-5155(98)00038-0","journal-title":"Jpn J Ophthalmol"},{"key":"4670_CR377","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.2337\/db13-0014","volume":"62","author":"M Rodrigues","year":"2013","unstructured":"Rodrigues M, Xin X, Jee K et al (2013) VEGF secreted by hypoxic Muller cells induces MMP-2 expression and activity in endothelial cells to promote retinal neovascularization in proliferative diabetic retinopathy. Diabetes 62:3863\u20133873. https:\/\/doi.org\/10.2337\/db13-0014","journal-title":"Diabetes"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-022-04670-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-022-04670-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-022-04670-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T17:29:55Z","timestamp":1674581395000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-022-04670-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,31]]},"references-count":377,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["4670"],"URL":"https:\/\/doi.org\/10.1007\/s00018-022-04670-y","relation":{},"ISSN":["1420-682X","1420-9071"],"issn-type":[{"value":"1420-682X","type":"print"},{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,31]]},"assertion":[{"value":"12 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"22"}}